CLIN ICAL STUDY PROTOCOL 
TITLE PAGE 
Title  A Randomized, Double-Blind, Placebo- Controlled, Multiple 
Ascending Dose Study to Evaluate the Safety, Tol erability and 
Pharmacokinetic Properties of BIO89 -100 Administered 
Subcutaneousl y in Subjects with Nonal coholic Steatohep atitis 
(NASH) or with Nonalcoholic Fatty Liver Disease (NAFLD)and 
at High Risk of (NASH)  
Protocol Number:  BIO89 -100-002 
Compound Number: BIO89 -100 
Study Phase:  Phase 1b /2a 
Sponsor Name:  89bio LTD.  
Legal Registered Address:  [ADDRESS_8488], Herzliya 4676672 Israel 
Regulatory Agency 
Identifier Number:  IND: 131934 
Sponsor Representative:   
Approval Date:  11 March  2021 
Version:  5.0 
Amendment:  5.0 
This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) 
as directed by [CONTACT_9248] (ICH); United 
States (US) Code of Federal Regulations (CFR), and European Union (EU) Directives and Regulations (as applicable in the region of the study); national country legislation; and the 
Sponsor ’s Standard Operating Procedures (SOPs).  
CONFIDENTIALITY STATEMENT  
This document contains confidential and proprietary information (including confidential 
commercial information pursuant to 21CFR§20.61) and is a confidential communication of 
89bio LTD. The recipi[INVESTIGATOR_9198]. If there is any actual or suspected 
breach of this obligation, the recipi[INVESTIGATOR_9199] 89bio LTD . 
© [ADDRESS_8489] #: [STUDY_ID_REMOVED]

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  2 
 SIGNATURE [CONTACT_9351]:  
 
  
 
 89bio, Ltd.   Date  
  
  
 
  
 
Medical Monitor Name [CONTACT_9352] [CONTACT_9249] . 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  3 
 PRINCIPAL INVESTIGATOR [INVESTIGATOR_9200]  A Randomized, Double -Blind, Placebo -Controlled, Multiple 
Ascending Dose Study to Evaluate the Safety, Tol erability and 
Pharmacokinetic Properties of BIO89 -100 Administered 
Subcutaneousl y in Subjects with Nonal coholic Steatohep atitis 
(NASH) or with Nonalcoholic Fatty Liver Disease 
(NAFLD)and at High Risk of (NASH)   
Protocol Number  BIO89 -100-002 
Version and Date  5.0, 11 March 2021 
Amendment No.  5.0 
IND Number  IND: [ADDRESS_8490] of this 
protocol in accordance with ethical principles as outlined in the International Council for Harmonisation (ICH) guidelines on Good Clinical Practice, any applicab le laws and 
requirements ( including Part 54: Financial Disclosure by [CONTACT_6230] ) and any 
additional conditions mandated by a regulatory authority and/or Institutional Review Board/Independent Ethics Committee (IRB/IEC).
 
I acknowledge that I am responsible for the overall study conduct; I approve of and will 
comply with all conditions, instructions and restrictions described in this protocol. I am aware that my adherence to the above protocol is mandatory and that any changes in the protocol or 
consent form, except those necessary to eliminate apparent immediate hazards to human 
subjects, must first be approved in writing by 89bio, Ltd. A nd the respective IRB/IEC.  
I also agree that all information provided to me by [CONTACT_1034], including this document, Investigator’s Brochure, case report form , and verbal and written information, will be kept 
strictly confidential and confined to the clinical personnel involved in conducting the study. It 
is recognized that this information may be related in confidence to the IRB/IEC. I also 
understand that reports of information about the study or its progress will not be provided to 
anyone not involved in the study other than to th e Principal Investigator, or in confidence to the 
IRB/IEC or to the FDA or other legally constituted authority.  
 
 
 
Principal Investigator [INVESTIGATOR_9201], Country 
Protocol BIO89 -100-002 
 
 
89bio Confidential Page  4 
 PROTOCOL AMENDMENT SUMMARY OF CHANGES  
DOCUMENT HISTORY  
Document  Date 
Version 5.0 , Amendment 5.0  11 March 2021  
Version 4.1, Amendment 4. 0 22 October 2020  
Version 4.0, Amendment 4.0  06 October 2020  
Version 3 .0, Amendment 3.0  25 March 2020  
Version 2.0 , Amendment 2.0  09 February 2020  
Version 1.1, Amendment 1 .0 29 June  2019  
Original, Version 1. 0 16 May 2019  
 
Amendment:  5.0, 11 March 2021 
Overall Rationale for Changes implemented in Version 5.0 : 
Section # and Name  [CONTACT_9353] 4.3.1 Part 2 
Inclusion Criteria  IC # 3 b: Revised to specify fasting plasma 
glucose ≥126 mg/dL  or previous diagnosis 
of T2DM  
IC # 4b: Clarified the acceptable timeframe 
for historical liver biopsy  
IC # 5a: Clarified that MRI -PDFF will be 
adequate to assess steatosis if a Fibroscan model with CAP technology is unavailable 
IC # 7e and IC # 9: Clarified the definition 
of surgical sterilization and removed the 
requirement for medical documentation for 
eligibility consideration  
IC # 14: Added that COVID-19 protocols 
may be excepted with Medical Monitor (or designee) approval  
IC # 1 5: Removed the criterion  To clarify the inclusion criteria 
and to facilitate enrolment in 
Part 2 of the study  
Protocol BIO89 -100-002 
 
 
89bio Confidential Page  5 
 Section # and Name  [CONTACT_9353] 4.3.2 Part 2 
Exclusion Criteria Removed certain ECs: # 4 (cardiac 
arrhythmia), # 11 (major trauma or 
surgery), # 12 (acute illness), # 17 
(cigarette use), # 31 (blood donation)   
Clarified /revised  the wording in the 
following ECs  related to : (new #)   
Medical conditions: # 1, 2, 4, 6, 7, 8, 9, 1 0, 
12, and 13  
Prior and concomitant therapy: #15 , 18, 
and 19 
Diagnostic assessments:  # 21, 22, 23, 24, 
and 25 Other exclusions: 26, [ADDRESS_8491] 
Revised the wording on Vitamin E 
supplementation  
Specifie d that s hort term oral steroid bursts 
with/without taper as well as topi[INVESTIGATOR_9202] 4 Contraceptives  Removed the requirement for documentation of surgical sterilization 
 For consistency with the 
changes made in IC # 7e and IC # 9  
Signature [CONTACT_9354]89 -100-002 
89bio Confidential Page  6 TABLE OF CONTENTS  
1. PROTOCOL SUMMARY  ..........................................................................11  
1.1. Synopsis ......................................................................................................11  
1.2. Schedule of Activities (SoA) ......................................................................20  
1.2.1.  Part 1  ...........................................................................................................20  
1.2.2.  Part 2  ...........................................................................................................31  
2. INTRODUCTION  ......................................................................................35  
2.1. Study Rationale  ...........................................................................................35  
2.2. Background .................................................................................................35  
2.2.1.  Non-alcoholic Steatohepatitis  .....................................................................35  
2.2.2.  FGF21  .........................................................................................................36  
2.2.3.  BIO89 -100 ..................................................................................................37  
2.3. Benefit / Risk Assessment  ..........................................................................37  
2.3.1.  Risk Assessment  .........................................................................................37  
[IP_ADDRESS].  Potential Risk: Immunogenicity  .................................................................38  
[IP_ADDRESS].  Potential Risk: Bone Effects  .......................................................................39  
[IP_ADDRESS].  Potential Risk: Female Reproductive Effects  .............................................39  
[IP_ADDRESS].  Potential Risk: Injection Site Reactions  .....................................................40  
[IP_ADDRESS].  Potential Risk: Gastrointestinal Effects  ......................................................40  
[IP_ADDRESS].  Potential Risk of Liver Biopsy ...................................................................41  
2.3.2.  Benefit Assessment  .....................................................................................41  
2.3.3.  Update: Preliminary Data from Part 1  ........................................................41  
2.3.4.  Overall Benefit Risk Assessment  ...............................................................42  
3. PART 1  .......................................................................................................43  
3.1. Part 1 Objectives a nd Endpoints .................................................................43  
3.2. Part 1 Study Design ....................................................................................45  
3.2.1.  Scientific Rationale for Study Design  ........................................................46  
3.2.2.  Rationale for Study Population ...................................................................47  
3.2.3.  Justification of Treatment Duration  ............................................................47  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  7 
 3.2.4.  Justification for Dose  ..................................................................................48  
[IP_ADDRESS].  Justification for Weekly (QW) and Once Every Two Weeks (Q2W) 
Dosing Regimens ........................................................................................49  
3.2.5.  End of Study Definition ..............................................................................49  
3.3. Part 1 Eligibility Criteria  ............................................................................49  
3.3.1.  Part 1 Inclusion Criteria  ..............................................................................49  
3.3.2.  Part 1 Exclusion Criteria  .............................................................................51  
4. PART 2  .......................................................................................................57  
4.1. Part 2 Objectives and Endpoints .................................................................57  
4.2. Part 2 Study Design ....................................................................................60  
4.2.1.  Scientific Rationale for Part 2 Study Design  ..............................................60  
4.2.2.  Rationale for Part 2 Study Population  ........................................................61  
4.2.3.  Justification for Part 2 Treatment Duration  ................................................61  
4.2.4.  Justification for Part 2 Dose  .......................................................................61  
4.2.5.  Part 2 End of Study Definition ...................................................................62  
4.3. Part 2 Eligibility Criteria  ............................................................................62  
4.3.1.  Part 2 Inclusion Criteria  ..............................................................................62  
4.3.2.  Part 2 Exclusion Criteria  .............................................................................65  
5. STUDY INTERVENTION  ........................................................................69  
5.1. Study Intervention(s) Administered  ...........................................................69  
5.2. Administration Instructions  ........................................................................70  
5.3. Preparation/Handling/Storage/Accountability  ............................................70  
5.4. Measures to Minimize Bias: Randomization  ..............................................70  
5.5. Study Intervention Compliance ..................................................................71  
5.6. Concomitant Therapy  .................................................................................71  
5.6.1.  Prohibited Medications/Therapi[INVESTIGATOR_014]  ..............................................................72  
5.7. Stoppi[INVESTIGATOR_9203] ....................................................72  
5.7.1.  Monitoring and Discontinuation for Suspected Drug- induced Liver Injury 
(DILI)  ..........................................................................................................[ADDRESS_8492] DISCONTINUATION/WITHDRAWAL  ..................................................[ADDRESS_8493] Discontinuation/Withdrawal from the Study  .................................[ADDRESS_8494] to Follow-up .......................................................................................76  
7. STUDY ASSESSMENTS AND PROCEDURES  ......................................78  
7.1. Efficacy Assessments  .................................................................................78  
7.1.1.  Liver Biopsy and Scoring (Part 2 Only) .....................................................78  
7.2. Safety Assessments  .....................................................................................79  
7.2.1.  Physical Examinations  ................................................................................79  
7.2.2.  Vital Signs  ..................................................................................................79  
7.2.3.  Electrocardiograms  .....................................................................................79  
7.2.4.  Columbia- Suicide Severity Rating Scale (C -SSRS)  ...................................79  
7.2.5.  Clinical Safety Laboratory Assessments  ....................................................80  
7.3. Adverse Events and Serious Adverse Events .............................................80  
7.3.1.  Time Period and Frequency for Collecting AE a nd SAE Information  .......81  
7.3.2.  Method of Detecting AEs and SAEs ..........................................................81  
7.3.3.  Follow-up of AEs and SAEs .......................................................................81  
7.3.4.  Regulatory Reporting Requirements for SAEs ...........................................81  
7.3.5.  Pregnancy ...................................................................................................82  
7.4. Treatment of Overdose  ...............................................................................82  
7.5. Pharmacokinetics  ........................................................................................83  
7.6. Pharmacodynamics and Biomarkers  ...........................................................83  
7.6.1.  Immunogenicity Assessments  ....................................................................83  
7.6.2.  Pharmacodynamics .....................................................................................84  
[IP_ADDRESS].  Homeostatic Model Assessment for Insulin Resistance (HOMA -IR; Part 1 
only) ............................................................................................................85  
[IP_ADDRESS].  N-terminal Propeptide of Type III Collagen (Pro -C3) ...............................86  
[IP_ADDRESS].  Magnetic Resonance Imaging – Whole Liver Proton Density Fat Fraction 
(MRI -PDFF)  ...............................................................................................86  
7.6.3.  Exploratory Analyses  ..................................................................................87  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  9 
 8. STATISTICAL CONSIDERATIONS .......................................................88  
8.1. Statistical Hypotheses  .................................................................................88  
8.2. Sample Size Determination  ........................................................................88  
8.3. Populations for Analyses  ............................................................................89  
8.4. Statistical Analyses  .....................................................................................89  
8.4.1.  Safety and Tolerability Analyses  ................................................................90  
8.4.2.  PK Analyses ................................................................................................91  
8.4.3.  Immunogenicity Analyses ..........................................................................91  
8.5. Interim Analyses  .........................................................................................92  
8.6. Safety Monitoring Committee (SMC) ........................................................92  
9. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ..................................................................................93  
9.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ....93  
9.1.1.  Regulatory and Ethical Considerations  ......................................................93  
9.1.2.  Financial Disclosure  ...................................................................................93  
9.1.3.  Informed Consent Process ..........................................................................93  
9.1.4.  Data Protection  ...........................................................................................94  
9.1.5.  Dissemination  of Clinical Study Data ........................................................94  
9.1.6.  Data Quality Assurance  ..............................................................................94  
9.1.7.  Source Documents ......................................................................................95  
9.1.8.  Study and Site Closure ................................................................................95  
9.1.9.  Publication Policy  .......................................................................................96  
9.2. Appendix 2: Clinical Laboratory Tests .......................................................97  
9.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting ........................................................99
 
9.3.1.  Definition of AE  .........................................................................................99  
9.3.2.  Definition of Suspected and Unsuspected Adverse Reaction  ...................100  
9.3.3.  Definition of Events to Monitor  ...............................................................100  
9.3.4.  Definition of SAE  .....................................................................................100  
9.3.5.  Recording and Follow-Up of AE and/or SAE ..........................................101  
9.3.6.  Reporting of SAEs ....................................................................................103  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  10 
 9.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  ...............................................................................................104  
9.5. Appendix 5: Considerations in Response to Coronavirus Disease 2019 (COVID-19) Pandemic .............................................................................107
 
9.6. Appendix 6: Glossary ...............................................................................[ADDRESS_8495] OF TABLES  
Table  1 Study Cohorts .............................................................................................18  
Table  2 Part 1 Schedule of Activities for Cohorts 1 -4 .............................................20  
Table  3 Part 1 PK Sample Collection for Cohorts 1 -4 – QW Dosing Interval ........24  
Table  4 Part 1 Schedule of Activities for Cohorts 5 and 6 ......................................25  
Table  5 Part 1 PK Sample Collection for Co horts 5 and 6 – Q2W Dosing Interval
 ....................................................................................................................30  
Table  6 Schedule of Activities for Part 2 (Cohort 7)  ...............................................[ADDRESS_8496] 
Values  .........................................................................................................74  
Table  8 Adverse Event Reporting Periods ...............................................................81  
Table  9 Protocol-Required Laboratory Assessments ...............................................97  
 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  11 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose 
Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100 
Administered Subcutaneously in Subjects with Nonalcoholic Steatohepatitis (NASH) or with 
Nonalcohol ic Fatty Liver Disease (NAFLD) and at High Risk of NASH  
Rationale 
BIO89 -100, developed by 89bio, is a glycoPEGylated analogue of fibroblast growth factor 21 
(FGF21), a metabolic hormone secreted by [CONTACT_4852], adipose tissue, skeletal muscle, and the 
pancreas, that is regulated by [CONTACT_9250], and glucose and 
lipid metabolism ( Lee, 2014) ( Arner, 2008) ( Park, 2016) . Administration of exogenous FGF21 
is being explored as a method to treat obesity- associated insulin -resistance disorders, a 
category that includes Non- Alcoholic Fatty Liver Disease (NAFLD) , the most common chronic 
liver disorder worldwide, and its higher-risk variant Non- Alcoholic Steatohepatitis  (NASH) . 
There are currently no approved pharmaceutical treatments for NASH  (Friedman, 2018) . 
Several nonclinical and clinical studies have shown that administration of various FGF21 analogues had beneficial effects on serum lipid and insulin- resistance as well as on liver fat 
(Zhang 2014) ( Gaich, 2013) ( Sanyal, 2019) . 
This Phase 1 b/2a study has  2 parts. Part 1 is designed to assess the safety and tolerability of 
repeated subcutaneous (SC) escalating doses of BIO89 -[ADDRESS_8497] of repeated SC doses of one dose level of BIO89 -100, administered for 
20 weeks, on liver histology in subjects with b iopsy -proven NASH with NAFLD Activity 
Score (NAS) ≥4, fibrosis stage F1 with high risk, F2 or F3. 
The study includes safety, pharmacokinetic (PK), pharmacodynamic (PD), and 
immunogenicity characterizations to allow a preliminary assessment of a safe and efficacious 
dose range to be studied in further clinical studies. 
Rationale for Part 2 (Cohort 7) 
To obtain an initial understanding of the potential histological benefit of BIO89-100, an 
open-label cohort (Cohort 7) has been added under Part [ADDRESS_8498] of 
20 weeks of dosing with BIO89-100 at a dose of 27 mg/week (QW) on liver histological 
endpoints. Assessments for this cohort will include safety, tolerability, PK, and PD parameters (with some modifications in comparison to Cohorts 1 -6, see Cohort 7 Schedule of Activities 
[SoA], Table  6). This cohort will enroll 20  subjects with biopsy- proven NASH (NAS ≥4, 
fibrosis stage F1 with high ris k, F2 or F3) as determined by a baseline biopsy (to be done 
during screening; subjects with historical biopsies performed within 24 weeks of Day 1, that 
are available for central read and determined to meet inclusion criteria by [CONTACT_9251] , 
will also be eligible). Subjects will undergo a second liver biopsy within  after the last 
dose of study intervention. Histological assessment will include ≥2- point improvement in NAS 

Protocol BIO89 -100-[ADDRESS_8499] a 1 -point improvement in ballooning or lobular inflammation, and no worsening of 
fibrosis   (primary endpoint) ; improvement of fibrosis ≥1 stage without worsening of NAS 
(secondary endpoint); and NASH resolution without worsening of fibrosis 0F1 (secondary 
endpoint). Additional exploratory  histological endpoints (e.g., other endpoints related to NAS, 
fibrosis, or both; histological assessments in subgroups; e.g., subjects with ≥30% relative 
reduction in hepatic fat as assessed by [CONTACT_9252] [MRI] -proton density fat 
fraction [PDFF] on Week 1 2 compared to baseline) will  be evaluated. Biopsies will be assessed 
by a central reader; in addition, biopsies will  be assessed with artificial intelligence (AI) -based 
technology.  
Objectives and Endpoints  
Part 1 (Cohorts 1- 6) 
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
tolerability of ascending 
multiple SC injections of 
BIO89 -[ADDRESS_8500] NAFLD 
and at a high  risk of NASH  • Frequency and severity of adverse 
events (AEs) and serious adverse 
events (SAEs)  
• Number of subjects who discontinued 
due to AEs and due to related AEs 
• To characterize BIO89 -100 
PK • Maximal observed serum 
concentrations (C max) within a dosing 
interva l 
• Area under the serum drug concentration by [CONTACT_9253] a 
dosing interval (AUC
0-tau) 
• Time to achieve C max (tmax) 
• Terminal elimination half- life (t ½) 
Additional PK parameters may be calculated if deemed appropriate.  
The serum concentration -time data may also be 
used for population PK modeling with the results 
reported s eparately from the clinical study 
report.  
Secondary  
 
1 Resolution of NASH includes the total absence of ballooning (score=0) and absent or mild inflammation (score 0 
to 1) associated with at least a 2 point reduction in NAS, and no worsening if fibrosis (progression ≥ 1 stage).  
Protocol BIO89 -100-002 
 
 
89bio Confidential Page  13 
 Objectives  Endpoints  
• To evaluate the 
immunogenicity of BIO89 -
100 as measured by [CONTACT_9254]- drug antibodies (ADA)  • Assessment of the incidence and 
characteristics of ADA after dosing (e.g., titer and/or binding specificity, 
to the FGF21, PEG part of BIO89 -
100, and neutralizing 
immunogenicity ) 
• Impact of the presence of ADAs on serum BIO 89-[ADDRESS_8501] ion (e.g., 
anaphylaxis) is observed.  
• To characterize biomarkers, PD profile , and biological 
activity of BIO89 -100 
administered at ascending doses and with both QW and 
Q2W dosing intervals 
• To evaluate the time, dose, 
and exposure relationship of 
BIO89 -100 on biological 
activity, as assessed by 
[CONTACT_9255] e change from baseline in 
the following biomarkers/PD parameters:  
• Anthropomorphic measurements:  
− Body weight 
• Laboratory parameters : 
− Triglycerides  
− Non-high density lipoprotein (non-
HDL ) cholesterol  
− High density lipoprotein ( HDL -c) 
− Low density lipoprotein (LDL -c) 
− Hemoglobin A1c (HbA1c) 
− Homeostatic model assessment of insulin resistance (HOMA -IR) 
− Liver function tests: alanine 
transaminase (ALT), aspartate 
transaminase (AST)  
− Adiponectin 
− N-terminal propeptide of type III 
collagen (Pro -C3) 
− Free fatty acids  and Adipo- IR (fasting 
free fatty acids  fasting insulin)  
• Imaging measures : 
Protocol BIO89 -100-002 
 
 
89bio Confidential Page  14 
 Objectives  Endpoints  
− Magnetic resonance imaging – Proton 
density fat fraction (MRI -PDFF)  
Other  Safety  Endpoints  
 
Part 2 (Cohort 7) 
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
tolerability of SC injections of 
27 mg BIO89 -100, 
administered weekly for 20 weeks, in subjects with 
biopsy-proven NASH (NAS ≥4, fibrosis stage F1 with high 
risk, F2 or F3) • Frequency of AEs and SAEs 
• To characterize effect of BIO89 -100 on liver histology • At least a 2 -point improvement in 
NAFLD Activity Score (NAS) with 
at least a 1 -point improvement in 
ballooning or lobular inflammation, 
and no worsening of fibrosis 
Secondary  
• To characterize biomarkers, 
PD profile , and biological 
activity of BIO89 -100 Change and percentage change from baseline in the following biomarkers/PD parameters:  
• Anthropomorphic measurements:  
− Body weight 
• Laboratory parameters : 
− Triglycerides  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  15 
 Objectives  Endpoints  
− non-HDL cholesterol  
− HDL -c 
− LDL -c 
− HbA1c  
− Liver function tests: ALT, AST  
− Pro-C3 
• Imaging measures : 
− MRI -PDFF   
• To characterize effect of 
BIO89 -100 on liver histology • Improvement of fibrosis ≥1 stage 
without worsening of NASH 
• NASH resolution without worsening 
of fibrosis2 
• To characterize BIO89 -100 
PK • Trough concentration of BIO89-100 
Other  Safety  Endpoints  
 
2 Resolution of NASH includes t he total absence of ballooning (score=0) and absent or mild inflammation (score 0 
to 1) associated with at least a 2 -point reduction in NAS, and no worsening if fibrosis (progression ≥ 1 stage).  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  16 
 Objectives  Endpoints  
Overall Design 
This study has  2 parts: 
• Part 1  is a randomized, double- blind, placebo -controlled, multiple ascending dose 
(MAD) study to evaluate the safety, tolerability , PK and PD profiles, and 
immunogenicity of BIO89 -[ADDRESS_8502] of 6 cohorts and will evaluate 2 dosing schedules, weekly (QW; Cohorts 1 to 
4) and every 2 weeks (Q2W; Cohorts 5 and 6) (Table  1). 
• Part 2 is an open- label cohort (Cohort 7) in which BIO89 -100 will be administered 
SC weekly at a single dose level ( 27 mg QW ) to 20 subjects with biopsy-proven 
NASH (NAS ≥4, fibrosis stage F1 with high risk, F2 or F3), to evaluate effect on histological endpoints.  
The study will include a Screening period, a Treatment period, and a Follow-up period. After signing informed consent, subjects will undergo sc reening assessments to determine eligibility 
over a period of up to 60 days. 
Part 1 (Cohorts 1- 6) 
Eligible subjects for Cohorts 1 -6 will be randomized for each cohort as described in 
Section  5.4. Randomization to cohorts 3 and 5 will be stratified by [CONTACT_9256]-confirmed NASH 
with fibrosis status F1, F2 , or F3  as described in Section  5.4.The decision to randomize into the 
next cohort (dose level) will be approved by a Safety Monitoring Committee (SMC), 
compris ed of  Principal Investigator [CONTACT_6231] , the Clinical Research 
Organization (CRO) M edical Monitor, and the Sponsor Medical Monitor.  The SMC will 
review blinded safety data (adverse events , clinical laboratory  data , vital signs , and 
electrocardiograms [ECG]), summary of PK data , if available , and other blinded relevant data. 
There will be 2 dose escalation decisions. After Cohort 1 completes the Day 36 visit, the SMC 
will decide wheth er subjects can be randomized into Cohorts 2 and 5 ( both cohorts to start 
concurrently) . After at least [ADDRESS_8503] on placebo in each cohort, complete the Day 36 visit, the SMC will decide wheth er 
subjects can be randomized into Cohorts 3, 4, and 6 ( all three cohorts to start concurrently) . 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  17 
 For all subjects, treatment with study intervention may be continued for 8 additional weeks 
(total of 12 weeks) following review of individual safety data (AE s, ECG, physical 
examination , and safety laboratory) through Day 30 (4 weeks) by [CONTACT_9257] , CRO 
Medical Monitor  and Sponsor Medical Monitor. Subject s who experience clinically significant 
treatment- emergent AEs that are assessed as a potential risk to subject safety will be 
discontinued from study intervention. The decision to discontinue study intervention will be made by [CONTACT_9258] . 
Cohorts 1 to 4 (weekly regimen) : On Day -1, eligible subjects will be randomized (as described 
above) and be treated with weekly  (QW)  SC injection of study intervention starting on  Day 1 
and continuing through Day 85; subjects will be domiciled at the Phase 1 unit from Day -1 (day 
before 1st dose) to Day 2 and from Day 28 (day before the 5th dose) to Day 30. Subjects will 
attend ambulatory clinic visits for dosing and evaluations per the Schedule of Activities  (SoA; 
Section  1.2.1, Table  2). On the Day 8, Day 15, and Day [ADDRESS_8504] dose.  
Cohorts 5 and 6 (every 2 weeks regimen) : On Day -1, eligible subjects will be randomized (as 
described above) and be treated with S C injection of study intervention every 2 week s (Q2W)  
starting on Day 1 and continuing through Day 85; subjects will be domiciled at the Phase 1 unit 
from Day - 1 (day before 1st dose) to Day 2 and from Day 28 (day before the 3rd dose ) to 
Day 30. Subjects will attend ambulatory clinic visits for dosing and evaluations per the SOA 
(Section  1.2.1, Table  4). On the Day [ADDRESS_8505] dose. On Days 64 and 78 , subjects will be 
contact[CONTACT_9259]. 
Subjects in all cohorts will be followed up on Day 92 ([ADDRESS_8506] dose of study 
intervention) and Day 113, [ADDRESS_8507] dose of study intervention (End of Study visit). 
Subjects who are found to be neutralizing anti-drug antibodies (NAb)- positive at the End of 
Study visit will be followed for 3 -5 months after this visit or until stable or declining  as deemed 
by [CONTACT_941] M edical M onitor.  
Part 2 (Cohort 7) 
Part 2 is an open- label cohort that will enroll 20 subjects with biopsy-proven NASH and 
fibrosis (NAS ≥4, fibrosis stage F1 with high risk, F2 or F3). Subjects will either undergo a 
liver biopsy during screening or have a recent liver biopsy (within ≤ 24 weeks before Day 1, 
available to be evaluated for  eligibility by [CONTACT_9251]) that meets study inclusion criteria. 
Eligible subjects will be treated  with weekly  (QW)  SC injection of study intervention starting 
on Day 1 and continuing through Day 134 (20 weeks of treatment). Subjects will attend 
ambulatory clinic visits for dosing and evaluations and home visits for dosing as per the 
Schedule of Activities3 (SoA; Section  1.2.2, Table  6). Subjects will undergo a second liver 
biopsy within [ADDRESS_8508] dose of study intervention. Subjects will be followed up on 
Day 141 ([ADDRESS_8509] dose of study intervention) and Day 162 ( [ADDRESS_8510] dose of 
study intervention, End of Study visit).  
 
[ADDRESS_8511] at some or all timepoints.  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  18 
  
.
 More frequent 
testing (e.g., every month) or testing for a longer period of time may be requested in the event 
of safety -related concerns.  
Number of Subjects and Intervention Groups  
A total of approximately 103 subjects, consisting of : 6 subjects to receive active and 2 subjects 
to receive placebo  in Cohort 1; 12 subjects to receive active  and 3 subjects to receive placebo 
in Cohort 2; 9 subjects to receive active and 3 subjects to receive placebo in Cohorts 4 and 6; 
14 subjects to receive active and 4 subjects to receive placebo in Cohorts 3 and 5; and 
20 subjects to receive active (open -label) in Cohort  7. Dose escalation cohorts are shown in 
Table 1 . Based on emerging data and SMC recommendation, the Sponsor can decide to modify 
the dose of any subsequent cohort.  
Table  1 Study  Cohorts  
Cohort  Dose 
Levela Frequency and Route of Administration  Number of Subjects  
BIO89 -100 Placebo  
1 3 mg  Weekly (QW), SC to abdomen (1 injection)  
Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 
and 85 
Total doses (initial 4 weeks + 8 -week 
extension): 5 + 8 6 2 
2 9 mg  QW, SC to abdomen (1 injection)  
Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 
and 85 
Total doses (initial 4 weeks + 8 -week 
extension): 5 + 8 12 3 
3 18 mg  QW, SC to abdomen (1 injection)  
Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 
and 85 Total doses (initial 4 weeks + 8 -week 
extension): 5 + 8 14 4 
4 27mg QW, SC to abdomen ( 2 injection s) 
Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 
and 85 Total doses (initial 4 weeks + 8 -week 
extension): 5 + 8 9 3 
5 18 mg  Every 2 weeks (Q2W), SC to abdomen 
(1 injection)  
Days 1, 15, 29, 43, 57, 71, and 85. 
Total doses (initial 4 weeks + 8 -week 
extension): 3 + 4 14 4 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page  19 
 Cohort  Dose 
Levela Frequency and Route of Administration  Number of Subjects  
BIO89 -100 Placebo  
6 36 mg  Q2W, SC to abdomen (2 injections)  
Days 1, 15, 29, 43, 57, 71, and 85. 
Total doses (initial 4 weeks + 8 -week 
extension): 3 + 4 9 3  
7 (open-
label)  27 mg  QW, SC to abdomen ( 2 injections)  
Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 
85, 92, 99, 106, 113, 120, 127, and 134  
Total doses: 20  20 NA 
a The actual doses will be ±5% the mg dose due to technical considerations related to drug withdrawal from the 
vials into the syringes for injection . This difference is considered negligible for subject exposure.  
Study Duration  
Part 1 (Cohorts 1- 6) 
For each subject  in Part 1 , the total duration of study participation will be up to 172 days 
(24.5 weeks) , excluding t he potential study interruption due to the COVID-19 pandemic: 
Screening period: ≤ 60 days (8.5 weeks)  
Treatment period:  84 days (12 weeks) 
Follow-up period 28 days (4 weeks) 
Part 2 (Cohort 7) 
For each subject  in Part 2 (Cohort 7) , the total duration of study participation will be up to 
221 days (31.5 weeks) , excluding the potential study interruption due to the COVID-19 
pandemic: 
Screening period: ≤ 60 days (8.5 weeks)  
Treatment period:  134 days (20 doses in 19 weeks)  
Follow-up period  28 days (4 weeks 4) 
Safety  Monitoring Committee : Yes  (Cohorts 1-6) 
 
4 Subjects who are found to be NAb -positive at the End of Study visit will be followed every 3  months starting 
from when the site has been notified of the positive result, until: (1) neutralizing antibodies are no longer 
detectable or (2) the subject has been followed for a period of at least 1 year (± 4 weeks). More frequent testing 
(e.g., every m onth) or testing for a longer period of time may be requested in the event of safety- related concerns.  
Protocol BIO89 -100-002 
 
 
89bio Confidential Page 20 
 1.2. Schedule of Activities (SoA) 
1.2.1. Part 1  
Table  2 Part 1 Schedule of Activities for Cohorts 1 -4 
Cohort 1 -4 
Assessments  Screening Period  Treatment Period   FU 
Period  
Study Visit  
Study Day  
Informed consent  X                     
Medical history/demographics  X                     
Percutaneous liver biopsy 
(optional)b X                     
Prior medications  X                     
Inclusion and exclusion criteria  X  X                   
Complete physical examc X             X     X  X 
Symptom -directed  physical 
examd   X B P    B B B  B     B   
Body weighte X   B     B B B  B     B   
Waist and hip measurements  X   B         B      X X 
Fibroscanf X                  X  
12-lead ECG (single)g X   B X    B B B  B X    B X X 
Urine drug screen  and, alcohol 
breath test  X  Xh                  
Clinical laboratory testsi X X  B X    B B B  B X    B X X 
Cortisol (24 hour urine 
collection)j X                  X  
Urinalysis  X  X           X     X X 
HbA1C  X  X                X X 
Serologyk X                     
TSH  X                     

Protocol BIO89 -100-[ADDRESS_8512] in WOCBP onlyl X(S)  X      B B B  B     B B X X 
Vital signsm X  X X P X X X X X X X X P X X X X X X X 
Columbia -Suicide Severity 
Rating Scale (C -SSRS)    X               D50  X  
Randomization    X                   
Study Intervention 
administrationn    X     X X X  X     X X   
PK blood collectiono    X X X X X B B B  X X X X X B X  
PD and biomarker blood 
sampling :                     
IGF-1, total     B     B B   B      X  
Adiponectin     B     B    B      X X 
CK-18, ELF panel and Pro -C3    B         B      X 
Free fatty acid     B     B    B      X X 
Oral glucose tolerance test 
(OGTT)p    X                X  
Insulin (not part of OGTT)     B     B    B       X 
HOMA -IR calculation     X               X X 
MRI -PDFF ; visceral fat; and 
subcutaneous fatq X                  X  
Plasma sample for potential 
future bone biomarkers analysisr   X                X X 
Pharmacogenomic (DNA) blood 
sampling    X                  
Exploratory biomarker analysiss    X                X X 
Immunogenicity  t    B      B   B      Xu X 
Endogenous FGF21v    B                  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 22 
 Cohort 1 -4 
Assessments  Screening Period  Treatment Period   FU 
Period  
Study Visit  
Study Day  
Adverse event monitoringw X X X ←-=========================================== → X X 
Concomitant medication  X X X ←-===========================================→  X X 
Domiciledx   X X X       X X X        
Abbreviations: B = predose; D = Day; CK = cytokeratin; DNA = deoxyribonucleic acid; ECG=electrocardiogram; ELF = enhanced liver fibrosis; EOS = end of study; 
ET= early termination; FGF21 = fibroblast growth factor 21; FU = Follo w-Up; HbA1c=hemoglobin A1c; IGF -1 = insulin- like growth factor; MRI -PDFF = magnetic 
resonance imaging based proton density fat fraction; P = Pre -discharge; PK=pharmacokinetic; Pro -C3 = N‐terminal propeptide of type III collagen; S = serum; TSH = 
thyroid st imulating hormone; WOCBP=women of child -bearing potential.  
Table [ADDRESS_8513] a study window of ±[ADDRESS_8514] who withdraws before completion of the study, an Early Termination (ET) visit will be conducted, if possi ble; with the same assessments 
as the Day [ADDRESS_8515] a liver 
biopsy in the 24 months prior to screening .|For subjects who underwent a previous liver biopsy >[ADDRESS_8516] has met all other inclusion and exclusion 
criteria ,  
c. Complete physical exam done at screening to include recording height, weight, and calculating BMI.  
d. Symptom -directed physical exam will be done pre -dose and prior to discharge from the Phase 1 unit on domiciled dosing visits (1st and 5th dose), and pre -
dose on ambulatory dosing visits. Additional physical examinations will be performed i f clinically indicated . 
e. On domiciled and ambulatory visits, body weight will be measured pre -dose. 
f. Fibroscan should be performed during screening, prior to magnetic resonance imaging (MRI)  for all subjects . 
g. 12-lead safety ECGs will be recorded as single be dside measurements; on domiciled dosing visits (1st and 5th dose), ECG will be measured pre -dose and 
[ADDRESS_8517] -menopausal status  ; on domiciled 
dosing visits (1st and 5th dose), clinical laboratory will be collected pre -dose and [ADDRESS_8518] dose; on ambulatory visits, clinical laboratory will be 
collected pre -dose.  For all subjects , alanine  transaminase (ALT) and aspartate transaminase (AST) will be collected twice during the  Screening  period  (at 
least 2 weeks apart), with the 2nd assessment to be collected at Day -[ADDRESS_8519] assessment, if required, will be collected via unscheduled  visit 
(refer to Exclusion criterion 3). 
j. Ambulatory 24 -hour urine collection for cortisol to be done within 14 days from baseline, on Day 50 and Day 92/ET. It is recommended  that subjects 
collect urine for the 24 hours prior to D-7 to-3 visit  and bring the container with them to this visit. Alternatively , urine can be collected for the 24 hours 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 23 
 prior to the randomization visit (D -1) and brought to the site on D -1 (the result is not required for eligibility confirmation).   For Day 50 and D92/ET  – 
subject will start collection 24 hours before coming into the clinic and bring the sample to the visit.  
k. Serology tests will include Hepatitis B surface antigen, Hepatitis C Virus, and Human Immunodeficiency Virus (HIV) [ADDRESS_8520] will be conducted at screening; at all other timepoints urine pregnancy test will be done to guide clinical decisions to dose on 
dosing days. Prior to the 1st dosing, the baseline urine pregnancy test will be performed on D- [ADDRESS_8521] will be conducted. 
m. k Vital signs include supi[INVESTIGATOR_9204], pulse, body temperature, and respi[INVESTIGATOR_697]; vital signs will be measured pre -dose (prior to scheduled blood 
draws and study intervention administration); 1, [ADDRESS_8522] -dose and prior to discharge on domiciled dosing visits (1st and 5th doses); on dosing 
ambulatory visits , vital signs will be measured pre -dose (prior to scheduled blood draws and study intervention administration) and prior to discha rge; on 
non-dosing visits, vital signs will be measured prior to scheduled blood draws. Starting from randomization, blood pressure and pulse will be measured in 
duplicate, the first measurement will be taken up to [ADDRESS_8523]/seated position and resting for at least 5 minutes prior to measurements.  
n. Study intervention will be administered SC to the abdomen region by [CONTACT_9260].  
o. PK blood samples will be collected as shown in Table  3. Additional blood samples for PK analysis may be collected if clinically indicated (e.g., in case 
of SAE) . For PK sample collection instruction/procedures, refer to the relevant manual . 
p. Blood samples for OGTT test will be collected under fasting conditions (10 hours)  at the following timepoints: 0 minutes (just prior  to ingesting glucose), 
30 minutes, 60 minutes, 90 minutes 120 minutes  and 180 minutes.  On Day 92/ET the insulin will be captured from the OGTT.  
q. At Screening, MRI -PDFF to be done within 35 days of baseline  (Day 1) . On Days 50 and 92, MRI -PDFF to be done within ± 2 days of the planned visit 
date. If out of the window, MRI -PDFF should still be performed as close to the target day as possible, but protocol deviation should be recorded.  
r. Samples for carboxy -terminal collagen crosslinks (CTX) and N-terminal propeptide of type 1 collagen (P1NP) will be obtained at the designated 
timepoints for storage and potential future analysis. The D42 sample will be obtained pre -dose. 
s. Samples for RNA as well as plasma and serum samples will be collected for potential future exploratory assessments, to increase understanding of 
BIO89 -100 biological activity and to identify potential existing and/or emerging biomarkers.  
t.  
 
 
 
 
u. Immunogenicity sample on Day 92/ET will only be collected for subjects who early terminate from the study.  
v. Baseline samples of endogenous FGF21 will be analyzed;  
 
w. The sites may take non -personally identifying photographs of potential injection site reactions (optional)  
x. Subjects in Cohorts [ADDRESS_8524] dose and the 5th dose. Other study visits will 
be ambulatory. On Day 8, Day 1 5 and Day 2 2 (ambulatory dosing visits), subjects will remain at the site for observation fo r at least [ADDRESS_8525] dosing.  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 24 
 Table  3 Part 1 PK Sample Collection for Cohorts 1 -4 – QW Dosing Interval 
Study Day  Dosing 
Day Ambulatory 
visit Hours relative to 1st dose (Day 1) 
X  
  
 X 
 X 
 X 
X X 
X X 
X X 
X  
  
 X 
 X 
 X 
X X 
X X 
X X 
X X 
X X 
 X 
 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 25 
 Table  4 Part 1 Schedule of Activities for Cohorts 5 and 6 
Cohorts 5-6 
Assessments  Screening Period  Treatment Period  FU Period  
Study Visit  
Stud y Day  
Informed consent  X                      
Medical 
history/demographics  X                      
Percutaneous liver 
biopsy (optional)b X                      
Prior medications  X                      
Inclusion and 
exclusion criteria  X  X                    
Complete p hysical 
examc X   
          X       X  X 
Symptom -directed  
physical examd   X B P  
  
X B X  B     B  B   
Body weighte X   B   
  
X B X  B    B  B   
Waist and hip 
measurements  X   B         B     X  X X 
Fibroscanf X                 X  X  
12-lead ECG 
(single)g X   B X    X B   B X     X X 
Urine drug screen  
and alcohol  breath 
test X  Xh                  
Clinical laboratory 
testsi X X  B X    X B X  B X    X X X 
Cortis ol (24 hour 
urine collection)j X                 X X  
Urinalysis  X  X           X    X X X 
HbA1C  X  X                X  X X 

Protocol BIO89 -100-[ADDRESS_8526] in 
WOCBP onlyl X (S)  X       B   B     B  B X X  
Vital signsm X  X X P X X X X  X X X X P X X X X X X X X 
Columbia -Suicide 
Severity Rating Scale 
(C-SSRS)    X                X  X  
Randomization    X                    
Study Intervention 
Administrationn    X      X   X     X  X   
PK blood collectiono    X X X X X X  B X  X X X X X  X X  
PD and biomarker 
blood sampling :                       
IGF-1, total     B     X B   B        X  
Adiponectin     B     X    B      X  X X 
CK-18, ELF panel 
and Pro -C3    B         B      X  X 
Free fatt y acid     B     X    B      X  X X 
Oral g lucose 
tolerance test 
(OGTT)p    
X                  X  
Insulin  (not part of 
OGTT)     B     X    B      X   X 
HOMA -IR 
calculation     X               X  X X 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 27 
 Cohorts 5-6 
Assessments  Screening Period  Treatment Period  FU Period  
Study Visit  
Stud y Day  
MRI -PDFF ; visceral 
fat; and 
subcutaneous fat q X                   X  X  
Plasma sample for 
potential future bone 
biomarkers analysisr   X                X  X X 
Pharmacogenomic 
(DNA) blood 
sampling    X                    
Exploratory 
biomarker analysis s   X                X  X X 
Immunogenicityt    B      B   B      X  Xu X 
Endogenous FGF21v    B                   
Adverse event 
monitoringw X X X ←-===========================================→  X X 
Concomitant 
medication  X X X ←-===========================================→  X X 
Domiciledx   X X X  
    
 X X X         
Abbreviations: B = predose; D = Day; CK = cytokeratin; DNA = deoxyribonucleic acid; ECG=electrocardiogram; ELF = enhanced liver fibrosis; EOS = end of study; 
ET= early termination; FGF21 = fibroblast growth factor 21; FU = Follow -Up; HbA1c=hemoglobin A1 c; IGF -1 = insulin- like growth factor; MRI -PDFF = magnetic 
resonance imaging based proton density fat fraction; P = Pre -discharge; PK=pharmacokinetic; Pro -C3 = N‐terminal propeptide of type III collagen; S = serum; TSH = 
thyroid stimulating hormone; WOCBP= women of child -bearing potential.  
Table [ADDRESS_8527] a study window of ±1 day  
* Between Visits [ADDRESS_8528] who withdraws before completion of the study, an Early Termination (ET) visit will be conducted, if possible;  with the same assessments 
as the Day [ADDRESS_8529] a liver 
biopsy in the 24 months prior to screening. |For subjects who underwent a previous liver biopsy >[ADDRESS_8530] has met all other inclusion and exclusion 
criteria . 
c. Complete physical exam done at screening to include recording height, weight, and calculating BMI.  
d. Symptom -directed physical exam will be done pre -dose and prior to discharge from the Phase 1 unit on domiciled dosing visits (1st and 3rd dose), and 
pre-dose on ambulatory dosing visits. Additional physical examinations will also be performed if clinically indicated.  
e. On domiciled and ambulatory visits, body weight will be measured pre -dose. 
f. Fibroscan should be performed during screening, prior to magnetic resonance imaging (MRI)  for all subjects .  
g. 12-lead safety ECGs will be recorded as single bedside measurements. On domiciled dosing visits (1st and 3rd dose), ECG will be measured pre -dose and 
[ADDRESS_8531]- dose; on ambulatory dosing visits, ECG will be measured pre -dose. Additional ECG may be conducted if clinically indicated.  
h. On Day -1, urine drug screen can be done at a local laboratory, however, a sample should also be collected for central laboratory eva luation  
i. Clinical la boratory tests will include biochemistry, hematology, and coagulation, and FSH for determination of post- menopausal status ; on domiciled 
dosing visits (1st and 3rd dose), clinical laboratory will be collected pre -dose and [ADDRESS_8532] dose; on ambulatory visits, clinical laboratory will be 
collected pre -dose.  For all subjects , alanine transaminase (ALT) and aspartate transaminase (AST) will be collected twice during the Screening period (at 
least 2 weeks apart), with the 2nd assessment to be collected at Day -[ADDRESS_8533] assessment, if required, will be collected via unscheduled visit 
(refer to Exclusion criterion 3). 
j. Ambulatory 24 hour urine collection for cortisol to be done within 14 days from baseline, on Day 50 and Day 92/ET . It is recommended that subjects 
collect urine for the 24 hours prior to D- 7 to-3 visit and bring the container with them to this visit. Alternatively, urine can be collected for the 24 hours 
prior to the randomization visit (D -1) and brought to the site on D -1 (the result is not required for eligibility confirmation).  For Day 50 and D92/ET  – 
subject will start collection 24 hours before coming into the clinic and bring the sample to the visit.  
k. Serology tests will include Hepatitis B surface antigen, Hepatitis C Virus, and Human Immunodeficiency Virus (HIV) [ADDRESS_8534] will be conducted at screening; at all other timepoints urine preg nancy test will be done to guide clinical decisions to dose on 
dosing days.  Prior to the 1st dosing, the baseline urine pregnancy test will be performed on D- [ADDRESS_8535] will be conducted . 
m. Vital signs include supi[INVESTIGATOR_9204], pulse, body temperature, and respi[INVESTIGATOR_697]; vital signs will be measured pre -dose (prior to scheduled blood 
draws and study intervention administration); 1, [ADDRESS_8536] -dose and prior to discharge on domiciled dosing visits (1st and 3rd doses); on dosing 
ambulatory visits, vital signs will be measured pre -dose (prior to scheduled blood draws and study intervention administration) and prior to discharge; on 
non-dosing visits, v ital signs will be measured prior to scheduled blood draws. Starting from randomization, blood pressure and pulse will be measured in 
duplicate, the first measurement will be taken up to [ADDRESS_8537]/seated position and resting for at least 5 minutes prior to measurements . 
n. Study intervention will be administered SC to the abdomen region by [CONTACT_9260] .  
o. PK blood samples will be collected as shown in  Table  5. Additional blood samples for PK analysis may be collected if clinically indicated (e.g., in case 
of SAE). For PK sample collection instruction/procedures, refer to the relevant m anual . 
p. Blood samples for OGTT test will be collected under fasting conditions (10 hours)  at the following timepoints: 0 minutes (just prior to ingesting glucose), 
30 minutes, 60 minutes, 90 minutes 120 minutes and 180 minutes . . On D ay 92/ET the insulin will be captured from the OGTT.  
q. At Screening, MRI -PDFF to be done within 35 days of baseline  (Day 1) . On Days 50 and 92, MRI -PDFF to be done within ± 2 days of the planned visit 
date. If out of the window, MRI- PDFF should still be performed as close to the target day as possible, but protocol deviation should be recorded.  
r. Samples for carboxy- terminal collagen crosslinks (CTX) and N- terminal propeptide of type 1 collagen (P1NP) will be obtained at the designated 
timepoints for storage and potential future analysis. The D42 sample will be obtained pre -dose 
Protocol BIO89 -100-002 
 
 
89bio Confidential Page 29 
 s. Samples for RNA as well as plas ma and serum samples will be collected for potential future exploratory assessments, to increase understanding of 
BIO89 -100 biological activity and to identify potential existing and/or emerging biomarkers.  
  
 
 
 
u. Immunogenicity sample on Day 92/ET will only be collected for subjects who early terminate from the study.  
v. Baseline samples of endogenous FGF21 will be analyzed;  
  
w. The sites may take non -personally identifying photographs of potential injection site reactions (optional)  
x. Subjects  in Cohort [ADDRESS_8538] dose; other 
study visits will be ambulatory. On the Day [ADDRESS_8539] 
dosing.  
  

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 30 
 Table  5 Part 1 PK Sample Collection  for Cohorts 5 and 6  – Q2W Dosing Interval 
Study Day  Dosing Day  Ambulatory visit  Hours relative to 1st dose (Day 1) 
X  
  
 X 
 X 
 X 
 X 
X X 
 X 
X  
  
 X 
 X 
 X 
 X 
X X 
X X 
X X 
X X 
 X 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 31 
 1.2.2. Part 2  
Table  6 Schedule of Activities for Part 2 (Cohort 7) 
Cohort 7  
Assessments  Screening Period  Treatment Period  FU Period  
Study Visit  
 Study Day  
(mandatory in clinic  visits ) 
Informed consent  X     
Medical history/demographics  X     
Percutaneous liver biopsyb X   X  
Histology machine read (PathAI ) X   X  
Prior medications  X     
Inclusion and exclusion criteria  X  B   
Complete physical examc X   X  X 
Symptom -directed physical examd   B   
Body weight  X  B X X 
Waist and hip circumference  X  B X  
Lifestyle counseling  X X X   
Fibroscane X   X  
12-lead ECG (single)f X  B X X 
Urine drug screen and alcohol breath 
test X  Bg   
Clinical laboratory testsh X X B X X 
Urinalysis  X  B X X 
HbA1C  X  B X X 
Serologyi X     
TSH  X     
Pregnancy test in WOCBP onlyj X(S)   B X X 
Vital signsk X  B X X 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 32 
 Cohort 7  
Assessments  Screening Period  Treatment Period  FU Period  
Study Visit
 Study Day
(mandatory in clinic  visits )
Columbia -Suicide Severity Rating 
Scale (C -SSRS)  X      
Study intervention in-clinic  
(mandatory)  administrationl   X X   
Home or in-clinic study intervention 
administrationm   
   
PK blood collectionn   B X  
Pro-C3   B X  
Adiponectin    B X  
MRI -PDFFo  X   X  
Bone biomarkers analysisp   B X X 
Immunogenicity q   B X X 
Endogenous FGF21r   B    
Adverse event monitorings X X X  ←=============== X ============== → X X 
Concomitant medication  X X X ←================ X =============== → X X 
Abbreviations: B = predose; D = Day; AI = artificial intelligence; ECG=electrocardiogram; EOS = end of study;  ET= early termination; FGF21 = fibroblast growth 
factor 21; FU = Follow -Up; HbA1c=hemoglobin A1c; MRI -PDFF = magnetic resonance imaging based proton density fat fraction; PK=pharmacokinetic; Pro -C3 = 
N-terminal propeptide of type III collagen; S = serum; TSH = thyroid stimulating hormone; WOCBP=women of child -bearing potential.  
Table [ADDRESS_8540] a study win dow of ±1 day.  Window for MRI -PDFF will be ±[ADDRESS_8541] dose of study intervention . Liver biopsies (first and second) will be done after MRI -
PDFF .  
a. For any subject who withdraws before completion of the study, an Early Termination (ET) visit will be conducted, if possible;  with the same assessments 
as the Day [ADDRESS_8542] dose of study intervention. 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 33 
 Liver biopsies (first and second) will be done after MRI -PDFF. If out of a window, a liver biopsy should still be performed as close to the target date as 
possible, but a protocol deviation should be recorded.  
c. Complete physical exam done at screening to include recording height, weight, and calculating BMI.  
d. Physical examinations will be performed if clinically indicated.  
e. Fibroscan should be performed during screening, prior to magnetic resonance imaging (MRI) for all subjects. Fibroscan will be  repeated on D141/ET.  
f. 12-lead safety ECGs will be recorded as single bedside measurements. Additional ECG may be conducted if clinically indicated.  
g. On Day 1, urine drug screen can be done at a local laboratory. 
h. Clinical laboratory tests (performed under fasting conditions, ≥ 10 hours) will include biochemistry, hematology, and coagulation, and FS H for 
determination of post -menopausal status . For all subjects, alanine transaminase (ALT) and aspartate transaminase (AST) will be collected twice during 
the Screening period (at least 2 weeks apart), with the 2nd assessment to be collected at Day -[ADDRESS_8543] assessment, if required, will be collected 
via unscheduled visit (refer to Exclusion criterion 3). 
i. Serology tests will include Hepatitis B surface antigen, Hepatitis C Virus, and Human Immunodeficiency Virus (HIV) [ADDRESS_8544] will be conducted at screening; at all other timepoints urine pregnancy test will be done to guide  clinical decisions to dose on 
dosing days. On dosing days in the clinic, a urine pregnancy test will be obtained locally; in addition, a urine sample will be sent to the central lab.  If 
urine test is positive, a confirmatory serum pregnancy test will be conducted.  
k. Vital signs include blood pressure, pulse, body temperature, and respi[INVESTIGATOR_697]; vital signs will be measured pre -dose (prior to scheduled blood draws 
and study intervention administration. Blood pressure and pulse will be measured in duplicate, the first measuremen t will be taken up to [ADDRESS_8545]/seated 
position and resting for at least [ADDRESS_8546] (under supervision) at ambulatory clinic 
visit and will be administered at home by [CONTACT_9261].  Subjects will be observed for [ADDRESS_8547]’s home . If home administration is not feasible , not desired by [CONTACT_1560] , or deemed  inappropriate  option by [CONTACT_941] i nvestigat or for any reason, in-clinic study intervention administration may take place at some or all of 
these timepoints.    
n. PK blood samples will be collected at the specified timepoints. Additional blood samples for PK analysis may be collected if clinically indicated (e.g., in 
case of SAE) . For PK sample collection instruction/procedures, refer to the relevant manual.  
o. At Screening, MRI -PDFF to be done within 35 days of baseline (Day 1). On Days 85 and 141, MRI -PDFF to be done within ± 7 days of the  planned visit 
date. If out of the window, MRI- PDFF should still be performed as close to the target day as possible, but protocol deviation should be recorded.  
p. Samples for carboxy -terminal collagen crosslinks (CTX) , N-terminal propeptide of type 1 collage n (P1NP) and osteocalcin will be obtained at the 
designated timepoints.  
q.  
 
 
 
 

Protocol BIO89 -100-002 
 
 
89bio Confidential Page 34 
 r. Baseline samples of endogenous FGF21 will be obtained in all subjects;  
 
s. The sites may take non -personally identifying photographs of potential injection site reactions (optional). 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 35 
 2. INTRODUCTION  
2.1. Study Rationale  
BIO89 -100, developed by 89bio, is a glycoPEGylated analog of FGF21, a metabolic hormone 
secreted by [CONTACT_4852], adipose tissue, skeletal muscle, and the pancreas . FGF21 is regulated by 
[CONTACT_9262] , affects energy expenditure , and glucose and lipid metabolism  (Lee, 2014) 
(Arner,  2008) ( Park, 2016) , and therefore may play a role in metabolic disease, e.g., NAFLD, a 
common chronic liver disease affecting 30% of adult population worldwide  (Chalasani,  2012) . 
Several nonclinical and clinical studies have shown that administration of similar FGF21 analogs 
had beneficial effects on serum lipid and insulin -resistance as well as on liver fat  (Zhang 2014)  
(Gaich, 2013) ( Sanyal, 2019) . There are currently no approved pharmaceutical treatments for 
NASH ( Friedman, 2018) . 
This Phase 1b /2a study has [ADDRESS_8548] of repeated 
SC doses of one dose level of BIO89-100 (27 mg QW) , administered for 20  weeks, on liver 
histology in subjects  with biopsy- proven NASH with NAFLD Activity Score (NAS) ≥4, fibrosis 
stage F1 with high risk, F2 or F3.  
The study includes safety, PK, PD, and immunogenicity characterizations to allow a preliminary 
assessment of a safe and efficacious dose range to be studied in further clinical studies. 
2.2. Background 
2.2.1. Non-alcoholic S teatohepatitis  
NASH is a chronic liver disease, characterized histologically by [CONTACT_9263] ≥5% of 
hepatocytes, injury (ballooning) (Chalasani, 2012) . It is part of the spectrum of NAFLD  that 
includes NASH, and cirrhosis resultant from fatty liver ( Estes, 2018) . In North America, the 
prevalence of NAFLD is estimated at ~24%. NAFLD patients tend to be obese, with insulin resistance and/or type 2 diabetes mellitus ( T2DM ), dyslipi[INVESTIGATOR_035], hypertriglyceridemia, and 
hypertension, and NAFLD is increasingly recognized as the liver disease component of the 
metabolic syndrome (MetS) (Chalasani, 2018) .  
The pathophysiologic mechanisms that lead to NAFLD are thought to be similar to those in the 
development of T2DM, as insulin resistance is a hallmark in both disease states. Insulin 
resistance in adipocytes leads to dysfunction in the normal regulation of lipolysis, contributing to 
elevated circulating free fatty acids, accumulation of triglycerides in the liver ( Saponaro, 2015)  
and lipotoxicity, manifested as inflammation and cellular injury (By[CONTACT_7943], 2015) , and ultimately – 
fibrosis.  
NAFLD is usually asymptomatic, unless progression to cirrhosis has occurred. It is often diagnosed by [CONTACT_9264] (e.g., ultrasound or magnetic 
resonance imaging ( MRI )) in subjects, commonly with features of the meta bolic syndrome , in 
whom no alternative etiology for liver fat accumulation can be identified (e.g., alcoholic liver 
disease, medications). Validated noninvasive tests for diagnosis of steatohepatitis are not 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 36 
 currently available, and a liver biopsy is still needed to diagnose the inflammation and cellular 
ballooning features of NASH ( Torres, 2012) . 
There is a high unmet need in NASH ( Friedman, 2018) . The disease progresses to fibrosis and 
cirrhosis in approximately 20% of patients (Vernon, 2011; Khan, 2015) , and 45% of patients 
with cirrhosis will progress to decompensated cirrhosis within 10 years ( Rinella, 2015) . Eight 
percent of patients with advanced fibrosis will develop hepatocellular carcinoma (HCC) within 5 years ( Hashimoto, 2009) , and there is increasing evidence that non- cirrhotic subjects with 
NAFLD may also be at an increased risk of HCC ( Mittal, 2016) . Pre-cirrhotic NASH has a 
relative risk of death of 1.7 over 15 years compared to the general population, and approximately 20% of NAFLD patients die of liver -related causes (Soderberg, 2010) . A variety of therapeutic 
agents a re being developed for NASH, targeting metabolic pathways, inflammatory pathways or 
fibrosis. Positive results from the REGENERATE study, the first and largest successful pi[INVESTIGATOR_9205] [ADDRESS_8549] been reported ( Younossi, 2019) . 
However, a s of this time, there are no approved therapi[INVESTIGATOR_9206].  
2.2.2. FGF21  
FGF21 is a metabolic hormone , regulated by [CONTACT_9262], that affects energy expenditure 
and glucose and lipid metabolism. It is secr eted mainly by [CONTACT_4852] , but also by [CONTACT_9265], skeletal muscle, and the pancreas. The activation of fibroblast growth factor receptors 
(FGFRs) by [CONTACT_9266]21 requires the transmembrane protein cofactor β -Klotho, expressed  
predominantly in metabolic organs, including the liver, white adipose tissue, and the pancreas, 
conferring organ specificity to FGF21 ( Ogawa, 2007; Li, 2015) . 
In patients with  insulin resistance and NASH, circulating and tissue levels of FGF21 are 
increased  and correlate with disease severity, indicating  the presence of FGF21 resistance, which 
can be overcome by [CONTACT_9267]21. On this basis, 
administration of exogenous FGF21 has been explored as a method to treat obesity- associated 
insulin -resistance disorders, including NASH. 
Native  FGF2 1 has a short life (~2 hours) , limiting the potential to use it as a therapeutic agent . 
Consequently, various methods have been developed to extend the half- life of FGF21, including 
PEGylation. PEGylated FGF21 was shown to provide comparable efficacy to wild-type FGF21 
despi[INVESTIGATOR_9207], a likely result of greatly increased in vivo half- life ( Mu, 2012) . In humans, the effects of pegbelfermin ( BMS -986036; a PEGylated 
analog of FGF21 , which differs from BIO89 -100 in  
) on biopsy confirmed NASH patients (both genders; fibrosis stage 
F1-F 3) with hepatic fat fraction ≥10% (per MRI -PDFF) were recently assessed in a 16 -week 
randomized placebo -controlled study (n=74) ( Sanyal, 2019) . The study demonstrated a 
statistically significant reduction in liver fat versus placebo at week 16 (primary endpoint; measured by [CONTACT_9268] -PDFF), with up to 6.8% (p=0.0004) and 5.2% (p=0.008) absolute reduction 
for a 10 mg daily dose and 20 mg weekly dose, respectively. The study also showed 
improvements in Pro -C3, serum biomarker of fibrosis, magnetic resonance elastography 
(measure of liver stiffness), adiponectin, and liver enzymes (ALT, and AST). Improvements in triglycerides, LDL -c, and HDL- c were also noted  primarily with the [ADDRESS_8550] -in-human, single ascending dose study (TV47948- SAD-[ZIP_CODE]). 
In nonclinical pharmacology studies, BIO89-[ADDRESS_8551] shown good tolerability to treatment at doses that were time- folds 
higher than the effective doses in animal pharmacological models and over systemic human 
exposure to BIO89-100 following single administration of clinical doses (TV47948- SAD-[ZIP_CODE] 
study). Data from repeated nonclinical toxicology GLP studies in mice suggest that at high doses, BIO89-[ADDRESS_8552] on bone formation and linear growth, and on the female reproductive system (refer to Section  2.3.1). The determined no observed adverse effect 
level ( NOAEL ) in males and female  mice  is much higher than the suggested clinical doses in 
BIO89 -100-002. 
TV47948- SAD-[ZIP_CODE], a Phase 1, first -in-human, randomized, double-blind, placebo- controlled 
study to evaluate the safety, tolerability, and PK propertie s of BIO89 -100 following SC 
administration of single ascending doses (SAD), has recently been completed. The study randomized and treated 58 subjects, 43 of whom were dosed with BIO89-100 at 7 dose levels 
(0.45 mg; 1.2 mg; 3 mg; 9.1 mg; 18.2 mg; 39 mg; and 78 mg).  No significant safety issues have 
been identified.  
 
 
 
 
A detailed description of the chemistry, pharmacology, efficacy, and safety of BIO89-100 is 
provided in the Investigator’s Brochure (IB).  
2.3. Benefit / Risk Assessment  
Information about the expected benefits and potential risks (adverse event) of BIO89 -[ADDRESS_8553] been reported in a recently completed SAD study (Study TV47948- SAD-[ZIP_CODE]) with BIO89 -100. P otential risks  
based on nonclinic al data with BIO89 -[ADDRESS_8554] been reported as si gnificant safety concerns in the recently published Phase 2 proof-
of-concept study in which subjects with biopsy-proven NASH were treated for 16 weeks with 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 38 
 pegbelfermin, a PEGylated FGF21 analogue. Additional information regarding risks to subjects 
with BIO89 -100 may be found in the IB. 
[IP_ADDRESS]. Potential Risk: Immunogenicity  
As with any biologic drug, exposure to BIO89-100 may potentially provoke an immune response, with formation of ADAs, that may lead to loss of efficacy or adverse effects (e.g. , 
hypersensitivity, loss of endogenous FGF21 activity).  After single administrations to healthy 
subjects in study TV47948- SAD-[ZIP_CODE],  of BIO89-100- treated  subjects had positive 
ADA, all with  ADAs to BIO89 -[ADDRESS_8555] on PK or PD  
parameters that were evaluated in these studies. No severe hypersensitivity event has been reported in Cohorts 1- 6 (completed). Of note, formation of ADAs in nonclinical species is 
expected, and is generally not considered predictive for immunogenicity in humans. 
In study BIO89-100-102, t he following mitigation measures will be implemented to address the 
potential risk of severe hypersensitivity reactions, including anaphylaxis: 
a. Subjects with any prior exposure to an FGF21 analogue, if known, will be excluded 
from participating in the study .  
b. In Part 1 , subjects will be under observation and intensive monitoring (including 
multiple vital signs measurements) for 48 hours in 2 domiciled visits ([ADDRESS_8556] dose for Cohorts 5 and 6), and for [ADDRESS_8557] appropriate measures (personnel and equipment) to diagnose and address severe hypersensitivity reactions, including proximity to a hospi[INVESTIGATOR_9208] a subject may be evacuated, if needed. Details on identification and 
management of seve re hypersensitivity reactions after home administration will be 
provided in the Home Administration Manual.    
d. Severe hypersensitivity reactions (including anaphylaxis) will be an event to monitor .  
e. Stoppi[INVESTIGATOR_9209]89 -100.  
f. Hypersensitivity- related AEs will be captured as part of the general safety assessment 
in all subjects. 
g. Immunogenicity testing will be done frequently, at baseline and multiple timepoints 
during study treatment. In addition, an immunogenicity sample will be obtained in the event of a significant hypersensitivity reaction. Subjects who test positive for 
neutralizing antibodies to BIO89-100 at the EOS/ET visit will be  asked to return for 
additional follow -up testing. This testing should occur approximately every  
 
. More frequent testing (e .g., every 
month) or testing for a longer period of time may be requested in the event of safety -
related concerns. Follow- up testing will not be required where it is esta blished that 
the subject did not receive BIO89 -100 (Part 1) . All follow -up results, both positive 
and negative, will be communicated to the sites . A blood sample for ADA assessment 
will also be collected upon observation of any severe hypersensitivity reac tion (e.g., 
anaphylaxis). Subjects who test positive for binding, non-neutralizing antibodies and 

Protocol BIO 89-100-[ADDRESS_8558] clinical sequelae that are considered potentially related to an anti -BIO89 -100 
antibody response may also be asked to return for additional follow-up testing. 
[IP_ADDRESS]. Potential Risk: Bone E ffects  
The literature suggests that FGF21 may be involved in bone turnover ( Wei, 2012; Owen, 2013) . 
In nonclinical studies with BIO89 -100 in mice, non-adverse reductions in bone formation and 
resorption markers were observed in young, healthy mice , as well as decreases in tibia size and 
bone density. The relevance of these findings to humans is not known. Interestingly, in a study in 
40 healthy volunteers, fasting plasma FGF21 levels correlated positively with total bone mineral 
density (BMD) (R2=0.69, p=0.003) and spi[INVESTIGATOR_9210] (R2=0.76, p=0.001) in women, a correlation 
that remained significant after adjusting for age, ethnicity , and body composition ; there was no 
association between FGF21 concentrations and body composition in men ( Lee, 2013 ). 
Bone- related assessments have been conducted in studies of 2 long-acting FGF analogues in 
humans: PF-05231023, a long- acting synthe tic FGF21 analogue generated by [CONTACT_9269] 
[ADDRESS_8559] changes in bone turnover markers were 
observed with PF-05231023 over 4 weeks of treatment  (Kim, 2017) , especially in the context of 
weight loss, although the clinical significance of these findings is not established. With 
pegbelfermin no bone findings were observed relative to placebo treatment over 16 weeks of 
treatment. 
Bone- related AEs were not reported in a single ascending dose study with BIO89-100 (study 
TV47948- SAD-[ZIP_CODE]) however, this  short- term study  may not be informative for this type of 
risk. The determined NOAEL of BIO89-100 in males and female mice (up to 13 weeks) and 
monkeys (up to 28 days) is much higher than the suggested clinical doses in BIO89 -100-002. It 
is notable that in addition to the presence of an adequate safety margin relative to the highest 
dose to be administered in study BIO89-100-102, the risk of a clinically significant impact on bone is considered to be low in the setting of a 12-week study, as significant changes to bone 
typi[INVESTIGATOR_9211]. Nevertheless, as a precautionary measure, in study 
BIO89 -100-102 subjects younger than 21 year of age and subjects with a history of bone trauma, 
bone fracture, or bone surgery within 2 months of screening will be excluded. In Part 2, 
exclusion of subjects with bone disorders, including as osteoporosis, osteomalacia, and known, 
untreated severe vitamin D deficiency (serum 25 -hydroxy- vitamin D ≤5 ng/mL)  has been added 
as an additional precautionary measure, given the longer exposure.  
Bone- related AEs will be captured as part of the general safety assessment in all subjects. P lasma 
samples will be collected for potential future analysis o f bone turnover biomarkers , if deemed 
necessary . In Part 2, samples of bone turnover biomarkers will be analyzed. 
[IP_ADDRESS]. Potential Risk: Female Reproductive E ffects  
In nonclinical studies in mice exposed to high doses of BIO89-100,
 
. These are known 
effects of FGF21 in mice that have previously been described in the literature  (Wei, 2012;, 
Owen, 2013). Importantly, the established NOAEL  of 15 mg/kg in female mice provid es an 
adequate safety margin (16.2- and 52.4- fold margin  for AUC
168, ss and C max for the 27 mg QW  
clinical dose ) for the female reproductive findings that were observed in nonclinical studies with 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 40 
 BIO89 -100. Consequently, women of childbearing potential (WOCBP) will be allowed to enroll 
in study BIO89-100-102. It is worth noting that WOCBP  were enrolled in the recent  Phase 2a 
study with p egbelfermin (BMS -986036); no reproduction- related AEs  were reported  (Sanyal, 
2019) . Female reproductive AEs were not reported in a single ascending dose study with BIO89-
100 (study TV47948- SAD -[ZIP_CODE]). S pecific assessments of the female reproductive system  were 
not performed in this short-term study, which enrolled only females who were not of 
childbearing potential, and the study is not considered to be informative for this type of risk. WOCBP and their partners will be required to use highly effective contraception, as per current 
standards for investigational products with an unknown potential for embryotoxicity . Female 
reproductive system- related AEs will be captured as part of the general safety assessment in all 
female subjects. 
[IP_ADDRESS]. Potential Risk: Injection S ite Reactions 
As with other protein drugs that are administered subcutaneously, there is a potential for 
injection site reactions  (erythema, induration, ecchymosis , tenderness , warmth , swelling , and - at 
times  – more severe reactions , such as lipo dystrophy, ulceration, or necrosis). 
Injection site reactions following subcutaneous BIO89-100 injections in nonclinical species were 
non- adverse and reversible after a treatment -free period. Some m ild (CTCAE Grade 1) injection 
site reactions were reported in a single ascending dose study with BIO89-100 (study TV47948-
SAD-[ZIP_CODE]) that completely resolved  and did not require treatment; few injection site reactions 
were also reported in the placebo group.  
 
 
[IP_ADDRESS]. Potential Risk: Gastrointestinal E ffects  
Gastrointestinal (GI) effects have been reported in clinical studies with other FGF21 analogues. 
In a recent Phase 2a study with pegbelfermin (BMS -986036), in which NASH patients were 
administere d 10 mg daily or 20 mg weekly regimens of pegbelfermin ( N=49) or placebo ( N=26), 
the most frequently reported  AEs  were diarrhoea and nausea, which were more common in 
pegbelfermin -treated than in placebo- treated patients . There were 28 GI-related  AEs , including 
diarrhoea, nausea, frequent  bowel movements, upper abdominal pain, and vomiting, 11 of which 
were considered  to be treatment -related. The frequency of GI  AEs  was higher in patients treated  
with pegbelfermin than in patients who received placebo  but there was no clear association  
between frequency of AEs  and pegbelfermin dose. All GI  events were considered mild  or 
moderate  and only 1/11 treatment- related GI AEs required treatment for resolution (probiotics).  
No GI -related effects were observed in nonclinical studies with BIO89 -100 in either mice or 
monkeys.  
A few m ild, sporadic GI effects (nausea, dyspepsia, abdominal pain, constipation, diarrhea, 
flatulence, frequent bowel movements), most of which were considered not related to study drug 
and all of which resolved without treatment, were reported  in a single ascending dose study with 
BIO89 -100 (study TV47948- SAD-[ZIP_CODE]) . 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 41 
 [IP_ADDRESS]. Potential Risk of Liver Biopsy  
Following liver biopsy, t he overall rate of serious complications has been reported to be 
approximately 1% ( Seeff, 2010; Boyum, 2016)  and the overall mortality risk has been  estimated 
to be 0.2%  (West, 2010) . Most complications (83% to 96%) occur within 24 hours of the 
procedure ; 60% occur within 2 hours  (Pi[INVESTIGATOR_9212], 1986; Boyum, 2016) . Approximately 2 % to 3%  
percent of patients require hospi[INVESTIGATOR_9213]; pain or 
hypotension are the predominant causes ( Garcia -Tsao, 1993; Janes, 1993) . 
Pain is the most common complication following percutaneous liver biopsy with approximately 
25% of patients experiencing pain in the right upper quadrant or right shoulder ( Rockey, 2009) . 
The pain usually resolves completely within a few hours.  
The most common serious complication of liver biopsy is intraperitoneal hemorrhage. S evere 
bleeding that results in hemodynamic compromise or requires intervention has been reported 
following 0.01%  to 0.5 % of liver biopsies (Boyum, 2016). Bleeding usually becomes clinically 
apparent within 3 to 4 hours after the biopsy. Hypotension and/or tachycardia following a biopsy, 
particularly when associated with abdominal pain, are usually related to hemorrhage. 
2.3.2. Benefit Assessment  
There are currently no approved prod ucts for NASH in the US. As discussed  in previous 
sections, the FGF21  receptor  is a promising mode of action  for the treatment of NASH , and 
several FGF21 analogues are being evaluated for this indication. Recently , encouraging clinical 
data has been reported for a Phase 2 proof- of-concept study with pegbelfermin, a PEGylated 
FGF21 analogue , that was administered  to patients with biopsy-proven NASH for 16 weeks 
(Sanyal, 2019) . In this study, a significant reduction of hepatic fat (as assessed by [CONTACT_9268]- PDFF) 
was evident, as well as improvement in fibrosis -related  and metabolic parameters. While no 
clinical data for BIO89 -[ADDRESS_8560] on liver-related (e.g., reduction of hepatic fat) and 
metabolic parameters  in patients with NASH or with NAFLD at a high risk for NASH  (Part 1), 
and [ADDRESS_8561] on liver histology in 
patients with biopsy-proven NASH and fibrosis (Part  2). These patients may thus derive benefit 
from this treatment.  
2.3.3. Update : Preliminary D ata from Part 1  
At the time of finalization of this amendment, preliminary top -line data from Part 1 of this s tudy 
(Cohorts 1- 6) have become available. Analyses of the full dataset are ongoing.  
At Week 13, all BIO89-100 dose groups (Cohorts 1-6) showed signifi cant absolu te and relative  
reductions in MRI- PDFF. Up to 88% of BIO89- 100 subjects achieved  ≥30% MRI -PDFF 
reduction vs. baseline (p<0.001), a threshold of MRI -PDFF relative reduction that has been 
shown to be ass ociated with histological benefit ( Loomba, 2015; Loomba, 2017; Harrison, 
2019) . Signi ficant decreases in ALT vs.  placebo were observed with BIO89-100, which  were 
maximal with 27 mg QW (30 U/L decrease from baseline, p<0.001) and also prominent in the 
subgroup of subjects (n=17) with baseline ALT >45 U/L (35 U/L decrease from baseline, 
p<0.05). Reductions in Pro-C3, a fibrosis  marker, were also noted. Metabolic benefits  of 
Protocol BIO 89-100-[ADDRESS_8562] on lipi[INVESTIGATOR_805], with signi ficant reductions in triglycerides  (up 
to 28% in overall population, up to 49% in the subgroup [n=15] with  baseline TG  ≥200 mg/mL); 
non-HDL cholesterol and LDL -C (up to 15% and 16%, respectively), and increased adiponectin 
(up to +61%).  
BIO89 -[ADDRESS_8563] discontinued due to a related AE  (localized skin rash). Mild increased 
appetite (15.9% in pooled BIO89-100- treated subjects) was the most common AE. The 
frequency of gastrointestinal AEs compared favorably to placebo; diarrhea (BIO89 -100 12.7%; 
placebo  22.2%) and nausea (BIO89- 100 7.9%; placebo 16.7%) were the only GI AEs in ≥5%  of 
BIO89 -100- treated subjects. Injection site reactions, all mild, were reported in 6.3% of pooled 
BIO89 -100- treated subjects . No hypersensitivity reactions  were reported.  
2.3.4. Overall Benefit Risk Assessment  
As discu ssed, patients with NASH or with NAFLD at high risk for NASH  (Part 1) or biopsy-
proven NASH ( NAS ≥4 and fibrosis stage F1 with high risk, F2 or F3; Part  2) may derive benefit 
from treatment with BIO89 -100. The p reliminary data from Part 1 of this study (Cohorts 1 -6) 
demonstrat ing robust, clinically meaningful reductions in liver fat assessed by [CONTACT_9268] -PDFF and 
ALT  at thresholds that have been associated with histological benefit in patients with NASH , 
combined with additional metabolic benefits , provide further support for a potential benefit in 
patients with NASH.  
Available data from clinical studies with other FGF21 analogues, including a recent Phase [ADDRESS_8564] a good safety and 
tolerability profile  with single SC doses of BIO89 -100 up to 78 mg; mild injection site reactions 
and mild, sporadic GI effects were reported in BIO89-100- treated subjects. Preliminary data 
from Part 1 (Cohorts 1 -6) of study BIO89 -100-002 (the current study) also suggest a good safety 
and tolerability profile .  
As with any biologic drug, there is a potential risk of immunogenicity; measures have been implemented in this protocol to characterize this risk and appropriately identify and address any clinically significant events related to immunogenicity, including the potential for severe 
hypersensitivity reactions (including anaphylaxis). Bone and female reproductive findings have 
been observed at high doses in toxicology studies in mice; these risks are mitigated by [CONTACT_9270] s and additional preca utionary measures, as detailed in the 
section on potential risks.  
Taken together, considering the benefit, potential risks, and risk mitigation measures that have been implemented, the sponsor considers the benefit -risk profile for administering BIO89 -100 to 
patients with NASH or NAFLD at high risk for NASH  and patients with biopsy- proven NASH 
(NAS ≥4 and fibrosis stage F1  with high risk, F2 or F3) in study BIO89-100-102 to be favorable. 
The overall benefit -risk associated with administration of BIO89 -100 will be continually 
re-assessed with the emergence of additional data.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 43 
 3. PART 1  
3.1. Part 1 Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
tolerability of asce nding 
multiple SC injections of 
BIO89 -[ADDRESS_8565] NAFLD 
and at a high risk of NASH • Frequency and severity of AEs and SAEs  
• Number of subjects who discontinued 
due to AEs and due to related AEs 
• To characterize BIO89 -100 PK  • Cmax within a dosing interval 
• AUC 0-tau within a dosing interval 
• tmax 
• t½ 
Additional PK parameters may be calculated if deemed appropriate. 
The serum concentration -time data may also be 
used for population PK modeling with the results 
reported separately from the clinical study report.  
Secondary 
• To evaluate the 
immunogenicity of BIO89 -100 
as measured by [CONTACT_9271]  • Assessment of the incidence and 
characteristics of ADA after dosing  
(e.g., titer and /or binding specificity, 
to the FGF21 and PEG part of BIO89 -
100). 
• Impact of the presence of ADAs on 
serum BIO89 -100 concentrations and 
clinical safety . 
Additional ADA assessments will be performed if a severe hypersensitivity reaction (e.g., 
anaphylaxis) is observed.  
• To characterize biomarkers, PD profile and biological activity of BIO89 -100 
administered at ascending doses and with both QW and Q2W dosing intervals Change and percentage change from baseline in the following biomarkers/PD parameters:  
• Anthropomorphic measurements : 
− Body weight 
• Laboratory parameters : 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 44 
 Objectives  Endpoints  
• To evaluate the time, dose, and 
exposure relationship of 
BIO89 -100 on biological 
activity, as assessed by [CONTACT_9272]  − Triglycerides  
− Non-HDL cholesterol 
− HDL -c 
− LDL -c 
− HbA1c  
− HOMA- IR 
− Liver function tests: ALT, AST  
− Adiponectin 
− Pro-C3 
− Free fatty acids  and Adipo -IR (fasting 
free fatty acids   fasting insulin) 
• Imaging measures : 
− MRI -PDFF  
Other Safety  Endpoints 
Exploratory  Endpoints 

Protocol BIO 89-100-[ADDRESS_8566] of 6 cohorts and will evaluate 2 dosing schedules, QW  (Cohorts 1 to 
4) and Q2W  (Cohorts 5 and 6) (Table  1). Based on emerging data and SMC recommendation, 
the Sponsor can decide to modify  the dose of any subsequent cohort. 
Part 1  will include a Screenin g period, a Treatment period, and a Follow-up period. After signing 
informed consent, subjects will undergo screening assessments to determine eligibility over a 
period of up to  60 days. 
Eligible subjects will be randomized for each cohort as described in Section  5.4. Randomization 
to Cohorts 3 and 5 will be stratified as described in Section  5.4. The decision to randomize into 
the next cohort (dose level) will be approved by [CONTACT_9273], comprised of a t least  a Principal  
Investigator [CONTACT_6231] , the CRO Medical Monitor, and the Sponsor Medical 
Monitor. The SMC will review blinded safety data (adverse events, clinical laboratory  data, vital 
signs, and ECGs), summary of PK data , if available, and other blinded relevant data . There will 
be 2 dose escalation decisions. After Cohort 1 completes the Day 36 visit, the SMC will decide 
whether subjects can be randomized into Cohorts 2 and 5 (both cohorts to start concurrently ). 
After at least [ADDRESS_8567] on placebo 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 46 
 in each cohort, complete the Day 36 visit, the SMC will decide whether subjects can be 
randomized into Cohorts 3, 4, and 6 ( all three cohorts to start concurrently ). 
For all subjects, t reatment with study intervention  may be continued for 8 additional weeks  (total 
of 12 weeks) following review of individual safety data ( AEs, ECGs, physical examination, and 
safety laboratory)  through Day 30 (4 weeks)  by [CONTACT_9257], CRO Medical Monitor, and 
Sponsor Medical Monitor . Subject s who experience clinically significant TEAEs that are 
assessed as a potential risk to subject safety will be discontinued from study intervention and 
undergo an early termination visit. The d ecision to discontinue study intervention will be  made 
by [CONTACT_9274]. 
Cohorts 1 to 4 (weekly regimen) : On Day -1, eligible subjects will be randomized (as described 
above) and be treated with SC injection of study intervention QW starting on Day 1 through 
Day 85; subjects will be domiciled at the Phase 1 unit from Day -1 (day before 1st dose) to Day 2 
and from Day 28 (day before the 5th dose) to Day 30. Subjects will attend ambulatory clinic 
visits for dosing and evaluations per the SoA (Section 1.2.1, Table  2). On the Day 8, Day [ADDRESS_8568] dose. 
Cohorts 5 and 6 (every 2 weeks regimen) : On Day -1, eligible subjects will be randomized (as 
described above) and be treated Q2W with SC injection of study intervention starting on Day 1 
through Day 85; s ubjects will be domiciled at the Phase 1 unit from Day -1 (day before 1st dose) 
to Day 2 and from Day 28 (day before the 3rd dose ) to Day 30 . Subjects will attend ambulatory 
clinic visits for dosing and evaluations per the SOA (Section  1.2.1, Table  4). On the Day [ADDRESS_8569] dose. On Days 64 and 78 subjects will be contact[CONTACT_9275]. 
Subjects in all cohorts will be followed up on Day 92 ([ADDRESS_8570] dose of study 
intervention) and Day 113, [ADDRESS_8571] dose of study intervention (End of Study visit).   
Subjects who are found to be ADA positive at the end of study visit will be followed for 3-5 months after this visit or until stable or declining as deemed by [CONTACT_1689]. 
Assessments during the study period will be done as specified in the Schedule of Activities 
(SoA;  Table 2  for Cohorts 1-4 and Table 4  for Cohorts 5-6 ). 
For each subject, the total duration of study participation will be up to 172 days (24.5 weeks) 
excluding the potential dose interruption due to the COVID-19 pandemic: 
Screening period:  ≤ 60 days (8.5 weeks)  
Treatment period:  84 days ( 12 weeks)  
Follow -up period  28 days (4 weeks)  
3.2.1. Scientific Rationale for Study Design  
Part [ADDRESS_8572] of patients who are similar to the  intended target population for the drug. BIO89-100 is 
being developed for NASH wi th fibrosis ; in line with this approach, study BIO89-100-[ADDRESS_8573]  evidence of  ≥  10%  liver steatosis by [CONTACT_9268]- PDFF, together with either biopsy-
proven NASH (liver biopsy within 2 years before enrollment), or at least one of the following: 
(1) Obesity with T2DM or (2) Obesity with evidence of liver injury (latter defined as eit her 
increased ALT and/or Fibroscan vibration -controlled transient elastography (VCTE ) 
score ≥ 7 KPa ). It is notable that central obesity by [CONTACT_9276], and that the additional requirement for presence of T2DM, a well characterized 
risk factor for NASH and advanced fibrosis, or evidence of liver injury, is considered appropriate 
to define a population of NAFLD patients who are at high risk for NASH. This population of patients with biopsy- proven NASH or NAF LD with a high risk for NASH also meets regulatory 
expectations for patients to be enrolled in early proof-of-concept studies for NASH, in which change in liver fat as measured by [CONTACT_9268] -PDFF is a typi[INVESTIGATOR_9214]. Change in liver fat as 
determined by [CONTACT_9268] -PDFF has emerged as the leading noninvasive quantitative biomarker for 
liver fat quantification  as it  is accurate, reproducible, precise, has excellent inter -rater and intra -
rater reproducibility , and  has a robust correlation with MRI spec troscopy -based quant ification 
(the gold standard to quantify liver triglyceride content) for liver fat, with a correlation 
coefficient ranging from 0.98 to 0.99 ( Tapper, 2018) .The study population is thus also 
appropriate for proof -of-concept assessment of this and other pharmacodynamic endpoints.  
3.2.3. Justification of T reatment D uration  
The treatment duration will be 12 weeks, consisting of a 4-week study for initial safety assessment  (primary endpoint) with an 8- week extension phase for efficacy  and safety  
assessments. The study includes a n individual  safety checkpoint after 4 weeks  of treatment, to 
ensure that only individuals with an acceptable safety profile will proceed to the 8 -week 
extension phase . The study design will enable to obtain early proof -of-concept data, including 
assessment of change in liver fat (measured  by [CONTACT_9268] -PDFF) and additional biomarkers after 
[ADDRESS_8574] the dynamics of improvement in hepatic steatosis based on a drug’s mechanism of action. Studies assessing chang e in liver fat by [CONTACT_9268]- PDFF, including a recent study with another 
pegylated FGF21 product, pegbelfermin, typi[INVESTIGATOR_9215] 12 weeks or later ( Harrison, 
2018a ; Harrison, 2018b; Sanyal, 2019) . Recently, ≥30% reduction in hepatic steatosis by 
[CONTACT_9268] -PDFF at week 12 was found to be correlated with
 reduction i n the ballooning and 
inflammation components of NAFLD Activity Score, and to be predictive of NASH resolution 
on liver biopsy at 36 weeks. In line with these considerations, t he Sponsor plans to assess change 
in liver fat by [CONTACT_9268]- PDFF and other pharmacodynamic biomarkers after 12 weeks of treatment. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 48 
 3.2.4. Justification for Dose  
Six dose cohorts are planned : 4 cohorts to be dosed QW and 2 cohorts to be dosed Q2W 
(Table  1). Based on emerging data and SMC recommendation, the Sponsor can decide to modify  
the dose of any subsequent cohort. 
These dose regimens were selected based on nonclinical safety and pharmacology studies, 
interim review of PK and blinded safety data from the single ascending dose clinical study 
TV47948- SAD-[ZIP_CODE] and PK modelling. 
 
 
 
 
 
 
The exposure at the NOAEL for female and male mice as well as for monkey are compared to the observed AUC
(0-168) from the highest dose in  Study TV47948- SAD-[ZIP_CODE].  In determining 
the predicted safety margins for the highest dose planned in the Study BIO89-100-002 we used a 
partial fitting approach by [CONTACT_9277]47948- SAD -[ZIP_CODE] and a 
previously developed model in monkeys. When using the predicted  AUC (0 – 168) at steady state for 
the highest dose regimen, [ADDRESS_8575] administered dose, 36 mg Q2W,  
. The safety margins for both AUC (0 – 168) at steady  state  and for C max should provide more 
than adequate coverage for subjects in Study BIO89-100-002. 
Clinical safety observations also support the dose regimens for Study BIO89-100-002. Clinical 
safety in health y subjects is being established with single SC  doses up to 78 mg in study 
TV47948- SAD-[ZIP_CODE]. The study has been recently completed; review of blinded safety data did 
not identify clinically significant safety concerns.   Notably, the starting dose in BIO89-100-002, 
3 mg QW for 13 doses, represents a total exposure of  
 
A PK modeling and simulation framework was undertaken to estimate the systemic exposure anticipated with the proposed dose regimens for Study BIO89-100-002. Based on these analyses, 
across the proposed dose range, plasma concentrations (median, 2.5
th and 97.5th percentiles) are 
predicted to increase proportionally with dose up to and including 27 mg QW and 36 mg Q2W. 
The maximum proposed dose is anticipated to achieve maximal suppression of key PD responses associated with important clinical outcomes over the dosing interval, once steady- state is 
achieved. A 3 mg QW dose is anticipated to produce close to the half- maximal response whereas 
doses greater than 27 mg, administered QW, are not anticipated to produce substantially larger responses over a 27 mg dose. Therefore, the QW regimens are proposed to range from 3 mg to 27 mg, SC. Similar magnitude of maximal response is anticipated for a 36 mg dose administered 
Q2W.  
Based on these data, the dose regimens are anticipated to be safe, of sufficient duration to rea ch 
steady state, to maintain PD responses over the dosing intervals, and to cover the dose range 
where key PD  response s are predicted to be associated with important clinical outcomes to be 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 49 
 assessed in subsequent studies. Depending on emerging study findings , the range of doses in 
study BIO89 -100-102 may be modified, and other intermediate doses may be added.  
[IP_ADDRESS]. Justification for Weekly  (QW) and Once Every Two Weeks (Q2W) Dosing 
Regimens  
Nonclinical data from [ADDRESS_8576] of BIO89-100 (up to 2 mg/kg) was evaluated following either QW 
or Q2W dosing regimens, provides the rationale  for the dosing regimens with BIO89 -[ADDRESS_8577] completed the study if he or she has completed all study periods 
including the End of Study (EOS)/ Day [ADDRESS_8578] in the study. 
3.3. Part 1 Eligibility Criteria  
3.3.1. Part 1 Inclusion Criteria  
Subjects are eligible to be included in the study only if all of the following criteria apply:  
Age and Gender  
1. Subjects must be 21 to 75  years of age inclusive, at the time of signing the informed 
consent form (ICF).  
2. Male or female.  
Type of Subject and Disease Characteristics  
3. Evidence of steatosis by [CONTACT_9278]- PDFF:  
a. All subjects must complete a Fibroscan with Controlled Attenuation Parameter (CAP) 
measurement. Fibroscan must be done with a subject -appropriate probe during 
screening; CAP score should be ≥300  dB/m , unless a MRI -PDFF ≥10%  within the 
last 12 months is available  and the current CAP score is similar  to CAP score when 
previous MRI- PDFF was done . 
b. MRI -PDFF ≥10% at screening (MRI must be completed no more than 35  days prior 
to randomization)  
For the purpose of the se inclusion criteria, use the following definitions:  
T2DM: History of T2DM diagnosed at least 6 months prior to screening [diagnosis based on 
documentation of fasting plasma glucose (≥126 mg/dL), plasma glucose in the 75g OGTT (≥200 mg/dL) or HbA1c (≥ 6.5 %)]. Subjects must have a glycated hemoglobin (HbA1C) level 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 50 
 at <9.5%, without known macrovascular or clinically significant microvascular complications, 
and – if receiving antidiabetic medications – must be on a stable dose of antidiabetic medications 
before screening (6 months for Glucagon-Like Peptide 1 (GLP-1) analogs or Dipeptidyl 
Peptidase IV ( DPP-IV) antagonists; 3 months for other oral or injectable medications ; 
thiazolidinediones or insulin are NOT allowed in this study).  
Central Obesity: Waist circumference of >102  cm for males, >88 cm for females , or body mass 
index (BMI) >30 kg/m2. BMI should not exceed 45 kg/m2. 
Increased ALT: ALT ≥ 40 in males, ALT ≥ 30 in females. ALT level should not exceed 
200 U/L.  
4. NASH or high risk for NASH as reflected by [CONTACT_9279]:  
a. Diagnosis of NASH with fibrosis (stages F1, F2 or F3), without cirrhosis, by 
[CONTACT_9280]: 
a. Performed within 24 months prior to screening   
b. For subjects who did not undergo a liver biopsy in the 24 months prior to screening, a liver biopsy may be performed during screening if not contraindicated  (option al, requires pre -approval by  [CONTACT_2728] ). For subjects who 
underwent a previous liver biopsy >[ADDRESS_8579] different findings in a repeat biopsy based on medical judgment.  
b. Central obesity WIT H T2DM  
c. Central obesity WITH either increased ALT and/or Fibroscan VCTE score ≥ 7 KPa.  
Pregnancy and Contraception  
Contraceptive use by [CONTACT_9281].
 
5. All subjects (male or female) who are of childbearing potential must agree to use highly  
effective, double contraception (both male and female partners) during the study. Double contraception is defined as use of a condom by [CONTACT_9282], combined with use of 
one of the following forms of highly  effective contraception by [CONTACT_9283]:  
a. a. Oral contraceptive pi[INVESTIGATOR_3353],  
b. b. depot or injectable contraceptive,  
c. c. Intrauterine device (IUD),  
d. d. Contraceptive patch (e.g. Xulane®) or NuvaRing®, or  
e. e. documented evidence of surgical sterilization at least 6  months prior to screening 
visit (i.e. tubal ligation or hysterectomy ).  
Use of a condom in a male subject who underwent vasectomy is also acceptable as double 
contracep tion. Use of highly-effective, double contraception must continue for 30 days or 5 half-
lives (whichever is longer) after the last dose of investigational product. Female subjects should 
not donate oocytes during this time. Male subjects must not donate sperm during this time. 
Rhythm methods are not considered as highly- effective methods of birth control. Subject 
abstinence for the duration of the study and 30 days or 5 half- lives (whichever is longer) after 
last dose of investigational product is acceptabl e if it is the subject’s regular practice.  
Protocol BIO 89-100-[ADDRESS_8580] prior to each administration of study intervention. 
7. Females not of childbearing potential will be defined for this study as  postmenopausal 
(defined as cessation of regular menstrual periods for at least 12 months) and confirmed by [CONTACT_9284] (FSH) level OR sterile.  
Medical documentation indicating that the subject had undergone a surgical sterilization 
procedure will be required from female study subjects to be considered not of 
childbearing potential in this study.  
Presumptive fertile male subjects who are partnered with women who are not of 
childbearing potential,  either post-menopausal or through sterilization or other surgical 
procedures (e.g., hysterectomy) wi ll confirm that their partners have bee n determined to 
be sterile or post -menopausal based on medical judgment; this can be confirmed either by 
[CONTACT_9285], if presented by [CONTACT_423].  
Men will not be required to use other contraception when sexually active with a sterile or 
post-menopausal partner. 
Men who are sexually active with fertile women need to confirm that they will use 
2 forms of contraception as per protocol.  
Informed Consent  
8. Capable of giving signed informed consent which includes compliance with the requirements and restrictions  listed in the ICF and in this protocol.  
3.3.2. Part 1  Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. History of, or current symptoms of, cardiovascular disease or cerebrovascular disease 
including clinical congestive heart failure (CHF), symptomatic coronary artery disease 
(CAD), peripheral arterial disease, and/or abdominal aortic aneurysm (AAA), history of 
transient ischemic attack (TIA), peripheral vascular disease (PVD), or symptomatic carotid stenosis. 
2. Clinically significant respi[INVESTIGATOR_696]; hepatic  (other than NAFLD or NASH) ; renal; 
gastrointestinal; neurological; immunological; hematologic , infectious or psychiatric 
disorder(s) (e.g. schizophrenia, generalized anxiety disorder, panic disorder, etc.); or a 
history of any illness that, in the opi[INVESTIGATOR_689], might confound the results 
of the study, or pose additional risk to the subject by [CONTACT_9286]. Individual cases which the Investigator deems the subject appropriate for inclusion despi[INVESTIGATOR_040] a chronic 
medical condition should be discussed with and approved by [CONTACT_1689] . 
Subjects who are known to have tested positive for COVID-19 will be excluded, even 
they are asymptomatic.  
The following conditions are NOT EXCLUDED: 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 52 
 • Hypertension : Subjects with a history of hypertension, whose hypertension is 
controlled and are clinically stable, may be enrolled if they have been on a stable dose 
of no more than [ADDRESS_8581] 2 months before screening.  
• Dyslipi[INVESTIGATOR_035]: Subjects with dyslipi[INVESTIGATOR_035], who are clinically stable, may be enrolled, 
including subjects who have been on a stable statin dose at least 2 months before 
screening.  
• T2DM:  Subjects with T2DM may be enrolled if their HbA1c level does not exceed 
9.5 %, there are no known macrovascular or clinically significant microvascular 
complications and they have been on a stable dose of antidiabetic medications in the 6 
months before screening (for GLP- 1 agonists or DPP -IV antagonists) or 3 months for 
other oral or injectable treatments. Subjects treated with  thiazolidinediones or insulin 
are excluded  from this study . 
• Depression : Subjects with stable, controlled depression, who have not been 
hospi[INVESTIGATOR_9216] a stable dose of no more than 
one antidepressant in the 2 months before screening, may be enrolled. 
3. Greater than 40%  increase in ALT or AST between [ADDRESS_8582] 2 weeks apart, as per the table below:  
ALT/AST Screening Assessments  Eligibility status  
Assessment 1  Assessment 2  Assessment 3 (if applicable) 
Normal  Normal  Not applicable Eligible  
Normal  Abnormal and ≤40% 
increase from Assessment 1 Not applicable Eligible  
Normal  Abnormal and >40% increase from Assessment 1 Normal or ≤40% increase 
from Assessment 1  Eligible  
Abnormal  and >40% increase 
from Assessment 1  Excluded  
Abnormal   ≤40% increase from Assessment 1  Not applicable Eligible  
Abnormal  >40% increase from Assessment 1  ≤40% increase from 
Assessment 1  Eligible  
>40% increase from Assessment 1  Excluded  
Normal is defined as ≤ ULN; abnormal is defined as >ULN  
Note: Clinical judgment should be used for subjects with isolated AST increases in whom there is suggestion of 
another cause of AST increase (e.g. muscle injury as evident by [CONTACT_9287]).  
4. A pe rsonal or family history of arrhythmia, sudden unexplained death at a young age 
(before 40 years) in a first -degree relative, or long QT syndrome. 
5. History of bariatric surgery or plan to have bariatric surgery during conduct of study. 
6. History of type 1 dia betes.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 53 
 7. Weight loss of more than 5% within 3 months prior to Day -1 or more than 10% within 
[ADDRESS_8583] of study. 
8. History of a liver disorder other than NASH or clinical suspi[INVESTIGATOR_1884] a liver disorder other 
than NASH, including but not limited to hepatitis B and hepatitis C, autoimmune hepatitis, hemochromatosis, alcoholic liver disease, primary sclerosing cholangitis (PSC), 
primary biliary cirrhosis (PBC), or Wilson’s disease.  
9. History of liver tra nsplantation. 
10. History of cirrhosis or evidence of cirrhosis (clinical, imaging -liver appearance or 
splenomegaly), advanced fibrosis (F4) on biopsy, VCTE- based Fibroscan >12.5 kPa or 
Fibrosis -4 (Fib -4) index
5 >3.25. In cases in which a patient is determined to have stage [ADDRESS_8584] will be considered to be 
eligible based on the liver biopsy result.  
11. Major trauma or surgery in the 2 months before screening or at any time between screening and Day -1. 
12. Recent clinically significant acute illness (within 4 weeks of screening ) unless per the 
Investigator ’s clinical discretion a full recovery is apparent.  
13. History of bone trauma, fracture or surgery within [ADDRESS_8585] as cured from cancer, exceptions may be considered. Any exception would need to be approved in advance by [CONTACT_1034]’s M edical Monitor. 
15. History of alcohol use disorder ( per DSM -5) or ris ky drinking (defined as alcohol intake 
>[ADDRESS_8586] drinks on a single occasion in men; and alcohol intake >[ADDRESS_8587] drinks on a single occasion 
in women) within the [ADDRESS_8588] at screening and/or check-in. A unit of alcohol is defined as 14 gram or as 355 mL of beer (5%), 1 glass of wine (150 mL; 12%), or [ADDRESS_8589] liquor (45 mL; 40%). During the study, 
subjects will be encouraged to abstain from alcohol. A lcohol intake will be limited to 
2 drinks per  day for men and 1 drink per day for women. 
16. History of drug  abuse, or any other substance dependence (with the exception of caffeine) 
as defined by [CONTACT_9288]- IV-TR in the past [ADDRESS_8590] for 
drugs of abuse (i.e., amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine 
metabolites, opi[INVESTIGATOR_858], and phencyclidine) at screening and/or Day -1. 
17. Daily use of more than 10 cigarettes/day, or 2 cigars/day, or equivalent use of any tobacco product within 6 weeks prior to Screening . E-cigarettes or other vapi[INVESTIGATOR_9217] 15 mg of nicotine/day. 
18. Pregnant or breastfeeding, or planning to become pregnant or brea stfeed while enrolled in 
the study or within 30 days or 5 half- lives (whichever is longer) after last dose of study 
 
5 FIB4 score = Age × AST (IU/l)/platelet count (× 109/l) × √ALT (IU/l) 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 54 
 intervention. Presumptive fertile , sexually active male  subjects, whose female partner is 
pregnant, will be excluded.  
Prior/Concomitant Therapy  
19. Subject report of use of medications historically associated with secondary NAFLD for 
more than 2 consecutive weeks in the 12 months prior to screening (e.g., amiodarone, 
methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses 
greater than those used for hormone replacement, anabolic steroids, valproic acid, and 
other medications with known hepatotoxicity).  
20. Any prior exposure to a FGF21 analogue (e.g. BIO89 -100, LY2405319, LY3025876, 
BMS -986036, BMS-986171, PF-05231023, PF-06645849, AKR-001) or FGFR1 
activating product, if known. 
21. Any previous long- term (> 4 weeks) use of systemic steroid (glucocorticoid) medications 
such as prednisone.  
22. Vitamin E supplementation beyond Recommended Dietary Allowance (22.4 IU/day) 
within 6 months before screening.  
23. Any systemic medications, including over- the-counter (OTC) medications, prescription 
drugs, biologics, vaccines, herbal preparations, used within 14 days, or 5 half- lives, 
whichever is longer, be fore Day -1 and throughout the study with the FOLLOWING 
EXCEPTIONS : 
a. Acetaminophen (up to 4 g/day, use as indicated in the label)  
b. Ibuprofen (up to 1.2 g/day of ibuprofen use as indicated in the label)  
c. Aspi[INVESTIGATOR_248] (up to 81 mg/day) 
d. Antihypertensive medications (no more than 2 agents) on stable dose for at least 
2 months prior to screening 
e. Antidiabetic medications : stable d ose for 6 months prior to screening for GLP -1 
analogs or DPP -IV antagonists; [ADDRESS_8591] 2 months 
g. Asthma treatment with exception of oral corticosteroids  
h. Anti-depressants (no more than 1 agent) on stable dose for at least [ADDRESS_8592] be approved by [CONTACT_1689]  
j. Vitamins (other than vitamin E at a dose greater than recommended dietary 
allowance ) and food supplements are allowed if the subject had been taking a stable 
regimen  for at least 2  months before screening.  
Prior/Concurrent Clinical Study Experience  
24. Any investigational drug small molecule (new chemical entity) within 30  days and large 
molecule (biologics) within 90  days, or 5 half- lives, whichever is longer, prior to Day -1, 
if known. 
Diagnostic Assessments 
25. Any history of suicidal behavior or suicidal ideation with plan and intent based upon 
clinical history.  A “yes” response to  any of the suicidal ideation or suicidal behavior 
questions in the C -SSRS on Day -1. 
Protocol BIO 89-100-[ADDRESS_8593] from participating in the study: 
a. ALT or AST  ≥ 200 U/L  
b. Elevation of total bilirubin (TB) > ULN  
c. Normalize d ratio (INR) > ULN  
d. Alkaline phosphatase at screening >1.25  ULN  
e. Glomerular filtration rate (eGFR) ≤60 mL/min/1.73  m
2 as estimated by [CONTACT_9289]- EPI 
[INVESTIGATOR_9218] (Levey, 2009)  
f. Serum total triglycerides  ≥ 1000 mg/dL 
g. HbA1c ≥ 9.5%  
27. ECG abnormality that may, in the opi[INVESTIGATOR_689] , interfere with study 
participation, including intraventricular conduction delays (QRS interval ≥ 120 msec or 
PR interval >200 msec (220 msec in individuals with a heart rate <70  beats per minute), 
and resting QTcF interval of ≤320 msec and/or ≥450 msec for males or ≥470 msec for 
females.  
28. Vital sign abno rmalities on screening,  including: having a supi[INVESTIGATOR_9219] 
<90 or >150 mmHg, diastolic blood pressure (following at least a [ADDRESS_8594]) <50 or 
>95 mmHg, or resting heart rate <50 or >100 beats per minute. 
29. BMI at screening  <25 or  ≥ 45 kg/m2. 
Other Exclusions 
30. Known allergy or sensitivity to injected proteins, or any component of the formulation, or 
has a history of allergies (including food allergies) requiring acute or chronic treatment 
(except for seasonal allergic rhinitis).  
31. Donated or received any blood or blood products (e.g., white blood cells, platelets) within 
the [ADDRESS_8595] who cannot undergo MRI for any reason (e.g., contraindication, claustrophobia, 
excessive weight or body size for MRI mac hine).  
35. Subject who cannot fast for study procedures for any reason. Specifically, subjects with 
T2DM who have had one or more epi[INVESTIGATOR_9220]. Subjects with T2DM who are treated by [CONTACT_9290] 89-100-[ADDRESS_8596] safely for study procedures.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 57 
 4. PART 2  
4.1. Part 2 Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the safety and 
tolerability of SC injections of 
27 mg BIO89 -100, 
administered weekly for 20 weeks, in subjects with biopsy-proven NASH (NAS ≥4, 
fibrosis stage F1 with high 
risk, F2 or F3)   • Frequency of AEs and SAEs 
• To characterize effect of BIO89 -100 on liver histology  • At least a 2 -point improvement in 
NAFLD Activity Score (NAS) with at least a 1 -point improvement in 
ballooning or lobular inflammation, and no worsening of fibrosis 
Secondary  
• To characterize biomarkers, PD profile , and biological 
activity of BIO89 -100  Change and percentage change from baseline in the following biomarkers/PD parameters:  
• Anthropomorphic measurements : 
− Body weight 
• Laboratory parameters : 
− Triglycerides  
− non-HDL cholesterol  
− HDL -c 
− LDL -c 
− HbA1c  
− Liver function tests: ALT, AST  
− Pro-C3 
• Imaging measures : 
− MRI -PDFF  
• To characterize effect of BIO89 -100 on liver histology • Improvement of fibrosis ≥1 stage 
without worsening of NAS H 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 58 
 Objectives  Endpoints  
• NASH resolution without worsening 
of fibrosis6 
• To characterize BIO89 -100 PK  • Trough concentration of BIO89-100 
Other  Safety  Endpoints  
Exploratory Endpoints  
 
6 Resolution of NASH includes the total absence of ballooning (score=0) and absent  or mild inflammation (score 0 
to 1) associated with at least a 2 -point reduction in NAS, and no worsening if fibrosis (progression ≥ 1 stage).  

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 59 
 Objectives  Endpoints  
 
7 ≥30% relative reduction in liver fat by [CONTACT_9268] -PDFF at D85  
8 Resolution of NASH includes the total absence of ballooning (score=0) and absent or mild inflammation (score 0 
to 1) associated with at least a 2 -point reduction in NAS, and no worsening if fibrosis (progression ≥ 1 stage).  

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 60 
 Objectives  Endpoints  
4.2. Part 2 Study Design 
Part 2 is an open- label cohort that will enroll 20 subjects with biopsy -proven NASH and fibrosis 
(NAS ≥4, fibrosis stage F1 with high risk, F2 or F3). Subjects will either undergo a liver biopsy 
during screening or have a recent liver biopsy (within ≤ 24 weeks before Day 1, available to be 
evaluated for eligibility by [CONTACT_9251]) that meets study inclusion criteria. E ligible 
subjects will be treated  with weekly  (QW)  SC injection of study intervention starting on Day 1 
and continuing through Day 134 (20 weeks of treatment). Subjects will attend ambulatory clinic 
visits for dosing and evaluations and home visits for dosing9 as per the Schedule of Activities 
(SoA; Section  1.2.2, Table  6). Subjects will undergo a second liver biopsy within [ADDRESS_8597] dose of study intervention. Subjects will be followed up on Day 141 ([ADDRESS_8598] 
dose of study intervention) and Day 162 ([ADDRESS_8599] dose of study intervention, End of 
Study visit). Subjects who are found to be NAb- positive at the End of Study visit will be 
followed approximately every 3 months starting from when the site has been notified of the positive result, until: (1) neutralizing antibodies are no longer detectable or (2) the subject has been followed for a period of at least 1 year (± 4 weeks). More frequent testing (e.g., every 
month) or testing for a longer period of time may be requested in the event of safety -related 
concerns.  
4.2.1. Scientific Rationale for Part [ADDRESS_8600] been observed. Part 2  extends the study to subjects with  biopsy-proven NASH and 
fibrosis  (NAS ≥4, fibrosis stage F1 with high risk, F2 or F3), similar to the population that is 
typi[INVESTIGATOR_9221] , who will be treated with BIO89-[ADDRESS_8601] been associated with histological benefit in patients with NASH, with 
repeated dosing of BIO89-100 for 12 weeks, in a similar population to the intended population in 
Part 2 . Part 2 extends the study to subjects with biopsy-proven NASH and fibrosis (NAS ≥4, fibrosis stage F1 with high risk, F2 or F3). This population of pat ients meets current regulatory 
expectations for patients to be enrolled in later stage studies  for NASH, and will allow to assess 
changes in liver histology, as well as changes in liver fat as measured by [CONTACT_9268] -PDFF and other 
biomarkers in a population of pa tients aligned with NASH registration studies . Histological 
endpoints will include at least a [ADDRESS_8602] a 1 -point 
improvement in ballooning or lobular inflammation with no worsening of fibrosis (primary), improvement of fibro sis by [CONTACT_2669] 1  stage without worsening of NASH, and NASH resolution 
without worsening of fibrosis (secondary) , and additional exploratory endpoints . In addition to 
other exploratory histological endpoints, exploratory analysis of histological endpoints in the 
subset of MRI -PDFF responders ( ≥30% relative reduction in liver fat by [CONTACT_9268] -PDFF at D85 ) will 
be conducted. The study population is appropriate for assessment of these  and other PD 
endpoints. 
4.2.3. Justification for Part 2 T reatment Duration 
The treatment duration will be 20 weeks, with weekly (QW) doses. Favorable s afety and 
tolerability of 12 -week s of dosing with BIO89 -100 at a dose of 27 mg QW was shown in Part 1. 
Based on results of recently published studies of Phase 2 clinical s tudies in a similar population 
of NASH patients, including a study with another FGF21 analogue (AKR-001, Akero ), a 
treatment duration of 20 weeks is considered appropriate for an initial evaluation of the 
histological endpoints that will be assessed in this study.  
4.2.4. Justification  for Part 2 Dose 
Subjects in open-label Cohort 7 will be dosed with 27 mg BIO89-100 QW for 20 weeks. 
Administration of 27 mg QW to patients with NASH or NAFLD and high risk for NASH 
(phenotypic NASH) for [ADDRESS_8603] QW dose in Part 1, was  based 
on nonclinical safety and pharmacology studies, including a 13 -week interim analysis of the 
ongoing GLP 26-week toxicology study in mice ( Study 6700477), PK , and safety data from the 
single ascending dose clinical study TV47948- SAD-[ZIP_CODE] and PK modeli ng, and is provided in 
Section  3.2.4. Results of the GLP 26 -week toxicology study in mice (Study 6700477), that has 
been completed, are available in the IB , and support 20 weeks of weekly dosing with 27 mg 
BIO89 -100.    
In Part 1 of Study BIO89-100-002, 10 subjects were randomized to Cohort 4 (27 mg QW). 
Preliminary data show that, while  significant absolute and relative reduction in liver fat as 
assessed by [CONTACT_9268] -PDFF at week 13 was observed for all studied doses, maximal reduction was 
achieved with the  
 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 62 
  
 
 
 
 
 
 
 
 
 
 
I
t has been shown that MRI PDFF response ≥30% ( Loomba, 2015; Loomba, 2017; Harrison, 
2019) and ALT reduction ≥17 U/L ( Loomba, 2019) are associated with a higher rate of NASH 
resolution and fibrosis reduction. In view of this, and considering the robust, clinically 
meaningful effects on MRI- PDFF and ALT and the favorable safety and tolerability profile of 
the [ADDRESS_8604] completed the study if he or she has completed all study periods 
including the End of Study (EOS)/Day [ADDRESS_8605] in the study. 
4.3. Part 2 Eligibility Criteria  
4.3.1. Part 2 Inclusion Criteria  
Subjects are eligible to be included in the study only if all of the following criteria apply:  
Age and Gender  
1. Subjects must be 21 to 75 years of age inclusive, at the time o f signing the informed 
consent form (ICF).  
2. Male or female.  
Type of Subject and Disease Characteristics  
3. Increased metabolic risk; s ubjects must have at least 2 of the following:  
a. Central obesity: Waist circumference of >102  cm for males, >88  cm for females , or 
body mass index (BMI) >30 kg/m2. BMI should not exceed 50  kg/m2 
b. Fasting plasma glucose ≥126 mg/dL  or previously diagnosed T2DM   
c. Increased fasting  triglycerides  (≥150 mg/dL) or on treatment for hypertriglyceridemia  
d. Reduced fasting HDL cholester ol (<40 mg/dL for male and <50 mg/dL for female)  
e. Hypertension or treatment of previously diagnosed hypertension  

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 63 
 Only subjects meeting Criteri on 3 should be further evaluated for participation. Subjects 
who do not initially meet C riteri on 3 may be re-tested, based on investigator judgment. 
4. Evidence of fibrosis – must meet at least one of the following criteria : 
a. Fibroscan VCTE score ≥8.[ADDRESS_8606] 3 months10 AND 
Aspartate aminotransferase (AST) > 20 U/L for males or >17 U/L for females in the 
first screening measurement11 
b. A historical liver biopsy obtained more than 24 weeks and less than 2 years before Screening  with Stage 1, 2 or 3 fibrosis.  
5. Evidence of steatosis by [CONTACT_9278] -PDFF:  
a. All subjects must complete a Fibroscan with CAP measurement. Fibroscan must be done with a subject-appropriate probe during screening; CAP score should be ≥280 dB/m  at screening or within the last 3 months  unless an MRI -PDFF ≥8% within 
the last 12 months i s available and the current CAP score is similar to or greater than 
CAP score when previous MRI -PDFF was done.  
NOTE: If a Fibroscan model with CAP technology is not available, 
MRI -PDFF will be adequate to assess steatosis.   
b. MRI -PDFF ≥8% at screening (MRI must be completed no more than 35 days prior to 
baseline)  
6. Biopsy-proven NASH in a liver biopsy obtained within 24 weeks of baseline with 
fibrosis stage F1, F2, or F 3 and NAS ≥4, with a score of at least 1 in each of steatosis, 
ballooning degeneration, and lobular inflammation.  
Liver biopsy may be obtained during screening or be a historical percutaneous biopsy that is deemed suitable for interpretation by [CONTACT_9251] (in up to approximately 
20% of subjects
12), if the patient had no significant change in metabolic status (control of 
diabetes or hyperlipi[INVESTIGATOR_035], >5% weight loss or gain) or medications.   
Patients with fibrosis stage F1 with high risk will be eligible (no more than approximately 
20% of subjects). Fibrosis stage F1 with high risk is defined as fibrosis stage F1 AND  at 
least one of the following criteria: a. T2DM, b. BMI ≥30 kg/m2, c. ALT > 1.[ADDRESS_8607] at 
screening , d. elevated Pro -C3 (>14 ng/m L) within 6 months before screening. 
Pregnancy and Contraception  
Contraceptive use by [CONTACT_9281].  
7. All subjects (male or female) who are of childbearing potential mu st agree to use highly 
effective, double contraception (both male and female partners) during the study. Double 
 
[ADDRESS_8608] had fibroscan a VCTE score ≥ 8.[ADDRESS_8609] 3 months, screening VCTE score should be ≥ 7.[ADDRESS_8610] (e.g. , in the presence of elevated . creatine 
phosphokinase [CPK ] or oth er evidence of muscle injury), AST should be re -tested when there is no longer evidence  
of potential contribution of an extra -hepatic source. The first assessment for Exclusion criterion [ADDRESS_8611] eligible according to Inclusi on criterion 4 . 
12 Subjects with an eligible historical biopsy that was obtained within 24 weeks from baseline do not need to meet 
Inclusion Criteria 4 and 5.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 64 
 contraception is defined as use of a condom by [CONTACT_9282], combined with use of 
one of the following forms of highly effective contraception by [CONTACT_9283]:  
a. Oral contraceptive pi[INVESTIGATOR_3353],  
b. Depot or injectable contraceptive,  
c. Intrauterine device (IUD),  
d. Contraceptive patch (e.g. Xulane®) or NuvaRing®, or  
 
Use of a condom in a male subject who underwent vasectomy is also acceptable as double 
contraception. Use of highly effective, double contraception must continue for 30 days or 
5 half- lives (whichever is longer) after the last dose of study intervention . Female subjects 
should not donate oocytes during this time. Male subjects must not donate sperm during this time. Rhythm methods are not considered as highly effective methods of birth control. Subject abstinence for the duration of the study and 30 days or 5 half- lives (whichever is longer) after the 
last dose of study intervention is acceptable if it is the subject’s regular practice.  
8. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1. Females of childbearing 
potential must agree to underg o a pregnancy test prior to each administration of study 
intervention. 
9. Females not of childbearing potential will be defined for this study as postmenopausal (defined as cessation of regular menstrual periods for at least 12 months) and confirmed 
by [CONTACT_9291]-stimulating hormone (FSH) level OR surgically sterile.  For the purposes of the 
study, surgical sterilization includes hysterectomy, bilateral salpi[INVESTIGATOR_1656] , or bilateral 
oophorectomy or bilateral tubal occlusion . 
10. Presumptive fertile male subjects who are partnered with women who are not of childbearing potential, either postmenopausal or through sterilization or other surgical 
procedures (e.g., hysterectomy) will confirm that their partners have been determined to 
be sterile or postmenopausal based on medical judgment; this can be confirmed either by [CONTACT_9285], if presented by [CONTACT_423].  Men will not be required to use 
other contraception when sexually active with a sterile or postmenopausal partner. 
11. Men who are sexually active with w omen of childbearing potential need to confirm that 
they will use [ADDRESS_8612] be available for the entire duration of the study and be willing to undergo 2 liver biopsies, one at screening (unless a qualifying historical biopsy is available within 24 weeks before baseline, in which case subjects will undergo only the second liver 
biopsy) and a second biopsy the end of the study. 
14.  Subjects must not participate in any other clinical trial throughout the duration of this 
study. Coronavirus virus disease 2019 (COVID-19) protocols may be excepted with 
Medical Monitor (or designee) approval . 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 65 
 4.3.2. Part 2 Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Unstable or clinically significant cardiovascular or cerebrovascular disease:  
a. Unstable angina, myocardial infarction, coronary artery by[CONTACT_9292] (CABG) 
surgery, percutaneous coronary intervention (PCI) , transient ischemic attack (TIA) or 
cerebrovascular accident (CVA) w ithin [ADDRESS_8613] tested positive for coronavirus virus disease 2019 
(COVID-19) within 3  months prior to screening will be excluded, even if they are 
asymptomatic.  
3. Greater than 40%  increase in ALT or AST between [ADDRESS_8614] 2 weeks apart, as per the table below:  
ALT/AST Screening Assessments  
Eligibility Status  Assessment 1  Assessment 2  Assessment 3 (if applicable) 
Normal  Normal  Not applicable Eligible  
Normal  Abnormal and ≤40% 
increase from Assessment 1 Not applicable Eligible  
Normal  Abnormal and >40% increase from Assessment 1 Normal or ≤40% increase from Assessment 1  Eligible  
Abnormal and >40% increase from Assessment 1  Excluded  
Abnormal  ≤40% increase from Assessment 1  Not applicable Eligible  
Abnormal  >40% increase from Assessment 1  ≤40% increase from Assessment 1  Eligible  
>40% increase from Assessment 1  Excluded  
Normal is defined as ≤ ULN; abnormal is defined as >ULN .  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 66 
 Note: Clinical judgment should be used for subjects with isolated AST increases in whom there is suggestion of 
another cause of AST increase (e.g. , muscle injury as evident by [CONTACT_9287]).  
4. History of bariatric surgery within the prior 5 years (including gastric banding or sleeve 
surgery) or plan to have bariatric surgery during conduct of study. 
5. History of type 1 diabetes.  
6. Weight loss of more than 5% within 3 months prior to Day 1  or more than  10% within 
6 months prior to Day 1. 
7. History of a liver disorder other than NASH or clinical suspi[INVESTIGATOR_1884] a liver disorder other 
than NASH, including but not limited to hepatitis B and hepatitis C, autoimmune 
hepatitis, hemochromatosis, alcoholic liver dis ease, PSC, PBC, alpha 1-antitrypsin 
deficiency, or Wilson’s disease.  Subjects who were previously diagnosed with chronic 
HCV infection who achieved sustained viral response (SVR) following treatment with a direct- acting antiviral (DAA) regimen at least 2 y ears prior to screening are not excluded.  
8. Prior or planned  liver transplantation.  
9. History of cirrhosis or evidence of cirrhosis (clinical, imaging -liver appearance or 
splenomegaly), advanced fibrosis (F4) on biopsy, VCTE- based Fibroscan >20.[ADDRESS_8615] will be considered to be 
eligible based on the liver biopsy result.  
10. History of bone trauma, fracture , or surgery within 2 months of screening or other bone 
disorders, such as osteoporosis, osteomalacia, or known, untreated severe vitamin D 
deficiency (serum 25 -hydroxy- vitamin D ≤5 ng/mL).  
11. Have any known malignancy or history of malignancy, except for basal cell skin cancer 
that has been treated with no evidence of recurrence for at least [ADDRESS_8616] as cured from 
cancer, exceptions may be considered. Any exception would need to be approved in advance by [CONTACT_1034]’s M edical Monitor. 
12.  Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening. Defined as more than 14 units/week for females and more than 21units/week for males on average. 
13. History of drug  abuse, or any other substance dependence (with the exception of caffeine) 
as defined by [CONTACT_9288]- IV-TR in the past [ADDRESS_8617] at screening may 
be considered for enrollment with Medical Monitor (or designee) approval. Chronic, 
habitual use of cannabis/cannabinoids is exclusionary . 
14. Pregnant or breastfeeding, or planning to become pregnant or breastfe ed while enrolled in 
the study or within 30 days or 5 half- lives (whichever is longer) after last dose of study 
intervention. Presumptive fertile, sexually active male subjects, whose female partner is pregnant, will be excluded.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 67 
 Prior/Concomitant Therapy  
15. Subject report of use of medications historically associated with secondary NAFLD for 
more than 2 consecutive weeks in the 12 months prior to screening (e.g., amiodarone, 
methotrexate, systemic glucocorticoids  [>2 weeks of pharmacologic dosing], 
tetracycl ines, tamoxifen, estrogens at doses greater than those used for hormone 
replacement, anabolic steroids, valproic acid, and other medications with known 
hepatotoxicity). Short term oral steroid bursts with/without taper as well as topi[INVESTIGATOR_9222].  
16. Any prior exposure to a FGF21 analogue (e.g., BIO89 -100, LY2405319, LY3025876, 
BMS -986036, BMS-986171, PF-05231023, PF-06645849, AKR-001) or FGFR1 
activating product, if known. 
17. Any investigational drug small molecule (new chemical entity) within 30  days and large 
molecule (biologics) within [ADDRESS_8618] 6 mo nths prior to the 
qualifying liver biopsy (historical or screening ). 
19. Subjects may be enrolled if they have been on a stable anti-diabetic regimen for 3 months 
prior to biopsy (historical or screening). Stable regimen is defined as no addition or discontinuation of antidiabetic medications, but dose adjustments per standard of care are allowed. Insulin and DPP- IV antagonists are allowed if subject has been on a stable 
regimen for at least [ADDRESS_8619] has been on a stable dose for 6 months. Thiazolidinediones are not allowed. 
20. Subjects on antiplatelet or anticoagulant medications in whom there is a significant 
medical risk to stoppi[INVESTIGATOR_9223] (as required per 
local practice for liver biopsy) due to the nature of the treated medical condition should be excluded.  
Diagnostic Assessments 
21. Suicidal behavior or suicidal ideation with plan and intent based: A “yes” response to  any 
of the suicidal ideation or suicidal behavior questions in the C- SSRS within the [ADDRESS_8620]  ≥250 U/L  
 
 
 
 
   
 
 
 
 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 68 
 23. ECG abnormality that may, in the opi[INVESTIGATOR_689], interfere with study 
participation  or present potential significant patient safety risk .  Resting QTcF interval 
≥450 msec for males or ≥470 msec for females.  
24. Clinically significant v ital sign abnormalities on screening, including having a sys tolic 
blood pressure <90 or >150 mmHg, diastolic blood pressure (following at least a 
[ADDRESS_8621]) <50 or >95  mmHg.  
25. BMI at screening <25 or ≥  50 kg/m2. 
Other Exclusions 
26. History of anaphylaxis or known allergy or sensitivity to any component of the study 
drug. 
27. Any abnormality of the skin or abdominal wall that would affect SC administration to the 
abdominal area. 
28. An employee of the investigational center or has a family member who is involved with 
the conduct of this study. 
29. Inability to undergo a liver biopsy safely for any reason 
30. Subject who cannot undergo MRI for any reason (e.g., contraindication, claustrophobia, excessive weight or body size for MRI machine).  
31. Subject who cannot fast for study procedures for any reason. Specifically, subjects wi th 
T2DM who have had one or more epi[INVESTIGATOR_9220]. Subjects with T2DM who are treated by [CONTACT_9293].  
 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 69 
 5. STUDY INTERVENTION  
Study intervention  is defined as BIO89 -100 ( or matching placebo in Part 1), intended to be 
administered to a study subject according to the study protocol. 
5.1. Study Intervention(s) Administered  
Study intervention will be administered SC to the abdomen region by [CONTACT_9260]. 
In Part 2, some study intervention administrations may  occur in the subject’s home13. 
ARM  Active arm Placebo arm (control)  
Intervention  BIO89-100  Matching placebo  
Type  Biologic  Chemical solution  
Dose 
Formulationa Each 0.7  mL vial contains 18 mg of 
BIO89-100 in Tris buffer solution 
(containing sodium chloride, sucrose, and polysorbate 20) at a concentration of 26 mg/mL  Each 0.7 m L vial contains Tris buffer 
solution (containing sodium chloride, sucrose, and polysorbate 20)  
Unit Dose Strength(s)  mg Not applicable  
Dosage Level(s)b Part 1  
3 mg, 9  mg, 18 mg, 27 mg weekly 
(QW)  
18 mg and 36 mg every other week 
(Q2W)  
Note: Based on emerging data and SMC recommendation, the Sponsor can decide to modify the dose of any subsequent cohort  Part 1  
NA; matching placebo will be injected 
at matching frequency per assigned 
cohort.  
Part 2  
27 mg weekly (QW)  Part 2  
Not applicable 
Route of Administration SC injection  SC injection  
Sourcing  Provided centrally by [CONTACT_9294]89-100 is supplied as a sterile, preservative-free, frozen formulation in 
a single -use Type 1 clear glass vial  for 
SC injection. Each vial will be labeled as required per country requirement.  Placebo will be supplied as a sterile, 
preservative-free, frozen formulation in a single-use Type 1 clear glass vial for SC injection. Each vial will be labeled 
as required per country requirement . 
a Note, in the original batch: each 1.5 mL vial contains 36 mg of BIO89 -100 
b The actual doses will be ±5% the mg dose due to technical considerations related to drug withdrawal  from the 
vials into the syringes for injection . This difference is considered negligible for subject exposure.  
 
[ADDRESS_8622] 2 inches  from 
the umbilicus (belly button). 
In Part 2, SC injection of the study intervention will be performed by [CONTACT_9295].  Details on s elf-administration at home , including training 
requirements, are provided in the Home A dministration M anual.  
5.3. Preparation/Handling/Storage/Accountability  
The Investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before use of the study intervention. 
Only subjects enrolled in the study may receive study intervention and only authorized site staff 
may supply or administer study intervention during in- clinic visits  with the exception that 
administration of study int ervention  by a trained home health care worker will be considered on 
a case -by-case basis if circumstances related to the COVID -19 pandemic preclude dosing at the 
study site. In Part 2, study subjects may self- administer study intervention either in the clinic 
(under supervision) or at home. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and authorized site staff.  
The Investigator, institution, or the head of the m edical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for study intervention preparation and administration and the final disposition of unused study interventions are provided in the relevant manuals . 
Details on preparation , handling, storage, and accountability for in -home visits in Part 2 are 
provided in the Home A dministration Manua l. 
5.4. Measures to Minimize Bias: Randomization  
In Part 1, eligible subjects will be randomized in the order they are enrolled into the study. For 
Cohort 1, 8 eligible subjects will be randomized in  a 3:1 ratio to 
active ( BIO89 -100) : control (placebo). For Cohort 2, 15 subjects will be randomized in a 4:1 
ratio to active  (BIO89 -100) : control (placebo).  For Cohorts 4 and 6, 12 eligible subjects will be 
randomized in each cohort in a 3:1  ratio to active  (BIO89 -100) : control (placebo).  For Cohorts  3 
and 5, 18 subjects will be randomized in each cohort in a 7:2 ratio to 
active (BIO89 -100) : control (placebo), stratified by [CONTACT_9256]- confirmed NASH with fibrosis status 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 71 
 F1, F2 or F3 (Yes, No) ( Kleiner, 2005) , with each stratum of 9 subjects in each cohort. All 
subjects in Part 1 will be centrally assigned to randomized study intervention using an Interactive 
Response Technology ( IRT). 
Part [ADDRESS_8623] 
at the study site will prepare the study intervention for SC administration.  
Part 2 will be open -label with all subjects receiving the same dose of BIO89 -100. 
5.5. Study Intervention Compliance 
When subjects are dosed at the site, they will receive study intervention directly from the Investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the electronic case report form (eCRF ). The dose of study intervention and study subject identification will be 
confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention . 
Details on  study intervention compliance at  home visits in Part 2 are provided in the Home 
Administration Manual. In cases in which a dose is administered outside of the allowed visit time 
window, adjustments to the remaining visit dates may be required. The investigator should discuss with the Sponsor if the dosing schedule has changed markedly (e.g., ≥1 week) compared 
to the original schedule.  
5.6. Concomitant Therapy  
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, and 
herbal supplements) that the subject  is receiving at the time of enrollment or receives during the 
study must be recorded along with at least the following information : 
• Reason for use 
• Dates of administration including start and end dates  
• Dosage information including dose and frequency 
It has previously been reported that NAFLD is associated with reduced CYP3A drug metabolism activity in vivo and hepatic CYP3A4 expression in humans ( Woolsey, 2015) . In addition, based 
on the work by [CONTACT_9296]21 may decrease 
hepatic CYP3A4 activity ( Wools ey, 2016)  . The underlying mechanism has not been fully 
elucidated . 
However, subjects receiving concomitant administration of CYP3A4 substrates with narrow therapeutic index should be closely monitored for any potentially related safety events, and dose 
adjustment of the CYP3A4 substrate should be considered as needed.  
The CRO Medical Monitor should be contact[CONTACT_9297]. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 72 
 5.6.1. Prohibited Medications /Therapi[INVESTIGATOR_9224]: 
• Bariatric surgery  (including gastric banding or slee ve surgery)  
• Medications historically associated with secondary NAFLD (e.g., amiodarone, 
methotrexate, systemic glucocorticoids  [>2 weeks of pharmacologic dosing], 
tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone 
replacement, anabolic steroids, valproic acid, and other medications with known 
hepatotoxicity ). Short term oral steroid bursts with/without taper as well as topi[INVESTIGATOR_9225] . 
• Vitamin E supplementation should not be initiated,  or the dose increased during the 
trial  
• Thiazolidinendiones.  
• Any investigational product, FG F21 analogues (e.g., LY2405319, LY3025876, 
BMS -986036, BMS -986171, PF-05231023, AKR -001, BIO89 -100), or FGFR1 -
activating product s. 
5.7. Stoppi[INVESTIGATOR_9226] D ose Modifications 
The Sponsor may suspend or terminate the study in the event of: 
• New toxicological or pharmacological findings or clinical safety findings that 
invalidate the earlier positive benefit -risk assessment . 
• Discontinuation of the development of BIO89 -100. 
• External circumstances that do not enable the study to be properly conducted under the existing protocol, including potential circumstances related to the COVID-19 
2020 pandemic. 
In Part 1, i f 3 or more subjects within a single cohort meet stoppi[INVESTIGATOR_9227], as described 
below, the SMC will meet to decide on study/dose-level discontinuation, suspension, dose modification  or repetition prior to proceeding to subsequent dosing:  
• New elevation of liver transaminase (ALT or AST) or bilirubin from baseline , as 
described belo w, without evidence of an alternative etiology for this elevation  
• Serious hypersensitivity reactions to BIO89 -100 
• Any SAE  on a case -by-case basis  
• A concerning pattern of laboratory or other safety findings 
5.7.1. Monitoring and D iscontinuation for S uspected Drug -induced Liver Injury  
(DILI )  
Per FDA recommendations, the following criteria for elevations in liver transaminases or bilirubin  will be used for closely monitoring, discontinuing or temporarily interrupting study 
intervention. 
Definition of b aseline ALT and AST values  
Protocol BIO 89-100-[ADDRESS_8624]  values performed during screening 
and the B aseline (Day 1) visit, as follows:  
ALT/AST Screening Assessments  Day 1 
ALT/AST Assessment  Baseline Value  
Assessment 1  Assessment 2  Assessment 3 (if applicable)  
Normal  Normal  Not applicable Any Average of Assessment 1, Assessment 2 and Day 1  (3 tests)  
Normal  Abnormal and ≤40% increase from Assessment 1  Not applicable Any Average of Assessment 1, Assessment 2 and Day 1  (3 tests)  
Normal  Abnormal and >40% increase from Assessment 1  Normal or ≤40% increase from Assessment 1  Any Average of Assessment 1, Assessment 2, 
Assessment 3 and 
Day 1  (4 tests)  
Abnormal and >40% increase from Assessment [ADDRESS_8625] excluded  
Abnormal  ≤40% increase from Assessment 1  Not applicable Any Average of Assessment 1, Assessment 2 and Day 1 (3 tests)  
Abnormal  >40% increase from Assessment 1  ≤40% increase from 
Assessment 1  Any Average of Assessment 1, Assessment 2, Assessment 3 and Day 1 (4 tests)  
>40% increase from Assessment [ADDRESS_8626] excluded  
New t ransaminase elevations in  subjects with baseline value within the normal range:  
For new elevations  in transaminases to greater  than 2x ULN, repeat measurement should be 
performed within  48-[ADDRESS_8627], subjects should be evaluated for other 
causes of  transaminase elevations and with tests of hepatic  function. If no other  cause is 
identified,  then the subjects  need to be m onitored closely  (see below) , and discontinuation of the 
study drug should be considered.  
 
[ADDRESS_8628] elevation 
(e.g. evidence of significant concurrent creatine phosphokinase elevation), decision regarding need to proceed with 
DILI work -up will be based on investigator judgement.  
Protocol BIO 89-100-[ADDRESS_8629] followed until resolution of symptoms or signs in 
the following situations:  
• ALT or AST >8x ULN  
• ALT or AST >5x ULN for more than 2 weeks 
• ALT or AST >3x ULN and (TB >2x ULN or INR >1.5) 
• ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
New t ransaminase elevations in subjects with baseline ALT or AST > ULN  
For new elevations  in transaminases to greater  than 2x baseline value or total bilirubin > 1.5x 
ULN, repeat measurement should  be performed within  48-[ADDRESS_8630], 
subjects should be evaluated for other causes of  transaminase  elevations and  with tests of hepatic  
function. If no other  cause is identified , then the subjects need to be m onitored closely  (see 
below), and discontinuation of the study drug should be considered. 
Study intervention should be discontinued, and the subject followed until resolution of symptoms 
or signs in the following situations: 
Table [ADDRESS_8631] 
Values  
Baseline  Value of ALT/AST Criteria to D iscontinue Study Intervention  
<2× upper limit of normal (ULN)  if ALT or AST increases to >5× baseline value 
≥2× ULN but <5× ULN  if ALT or AST increases to >3× baseline value 
≥5× ULN  if ALT or AST increases to >2× baseline value 
Other  if ALT or AST increase to >2× baseline value AND the increase 
is accompanied by a concomitant total bilirubin increase to >2× 
ULN OR the INR concomitantly increases by >0. 2.  
if ALT or AST increase to >2× baseline value in the presence of 
signs and symptom(s) such as fatigue, nau sea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophil (>5%)  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR = normalized ratio  
Close M onitoring for Suspected DILI:  
• Repeating liver enzyme and serum bilirubin tests two or three times weekly. 
Frequency of repeat testing can decrease to once a week or less if abnormalities 
stabilize or the trial drug has been discontinued and the subject is asymptomatic.  
• Obtaining a more detailed history of sympto ms and prior or concurrent diseases.  
• Obtaining a history of concomitant drug use (including nonprescription medications and herbal and dietary supplement preparations), alcohol use, recreational drug use, 
and special diets.  
• Rule out acute viral hepatitis types A, B, C, D, and E; autoimmune or alcoholic 
hepatitis; hypoxic/ischemic hepatopathy; and biliary tract disease.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 75 
 • Obtaining a history of exposure to environmental chemical agents. 
• Obtaining additional tests to evaluate liver function, as appropriate (e.g ., INR, direct 
bilirubin).  
• Considering gastroenterology or hepatology consultations. 
Note: If a patient lives in a remote area, laboratory testing can be performed locally and the 
results should be promptly communicated to the investigator site. 
5.8. Screen Fai lures  
Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently randomized. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure subject s to meet t he Consolidated Standards of Reporting 
Trials  (CONSORT) publishing requirements and to respond to queries from r egulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure) may  be 
rescreened  at a later date if the reason for screen failure is deemed temporary and is resolved 
prior to re -screening (e.g. respi[INVESTIGATOR_4416]). Subjects can only re- screen once. 
5.9. Intervention after the End of Study  
No additional intervention is planned  beyond the end of the study. 
Protocol BIO 89-100-[ADDRESS_8632]  DISCONTINUATION/WITHDRAWAL  
6.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a subject  to permanently discontinue study intervention . 
If study intervention is permanently discontinued, the subject will  remain in the study to be 
evaluated for safety , tolerability, and PK/PD assessments. See  the SoAs ( Table  2 for Cohorts 1 -4, 
Table  4 for Cohorts 5-6, and Table  6 for Cohort 7) for data to be collected at the time of 
discontinuation of study intervention ( ET visit).  
Please also refer to  stoppi[INVESTIGATOR_9228]  5.[ADDRESS_8633] Discontinuation/Withdrawal from the Study  
A subject  may withdraw or be withdrawn from the study for the following reasons:  
• Investigator decision  
• AE or intercurrent illness  
• Noncompliance with protocol requirements 
• Subject withdrawal of consent  
• Pregnancy 
• Sponsor termination or suspension of the study 
• Lost to  follow -up 
The reason for subject withdrawal from the study will be recorded i n the eCRF .  
Pregnancy is a mandatory criterion for permanent discontinuation of study intervention. 
At the time of withdrawal from the study, if possible , subject should attend the ET visit, as 
shown in the SoAs ( Table 2  for Cohorts 1 -4 , Table 4  for Cohorts 5-6, and Table 6  for Cohort 7 ). 
6.3. Lost to Follow -up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a subject  fails to return to  the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_9299]. 
• Before a subject  is deemed lost to follow -up, the Investigator or designee must make 
every effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_8634]’s last known mailing addre ss or local 
equivalent methods). These contact [CONTACT_9300] ’s 
medical record . 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 77 
 • Should the subject continue to be unreachable, he or she will be considered to have 
withdrawn from the study (and be labelled as lost to follow -up). 
• Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1 ( Section  9.1.8).  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 78 
 7. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoAs ( Table  2 for 
Cohorts 1-4, Table  4 for Cohorts 5-6, and Table  6 for Cohort 7).  Protocol waivers or 
exemptions are not allowed. 
• If multiple assessments are scheduled at the same timepoint, it is recommended that 
procedures be performed in the following sequence: 12- lead ECGs, vital signs, 
sample collection for laboratory and PD bioma rker tests, and sample collection for 
PK. 
• Immediate  safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the subject  should continue or discontinue 
study intervention. 
• Adherence to the study design requirements, including those specified in the SoAs , is 
essential and required for study conduct. 
• Any situation at the site level  with potential impact on subject safety or study 
conduct, including situations related to COVID -[ADDRESS_8635]/s or study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
subject s meet al l eligibility criteria. The Investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the subject ’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met  the protocol- specified  criteria and 
were  performed within the time  frame defined in the SoAs ( Table 2  for Cohorts 1 -4, 
Table 4  for Cohorts  5-6, and Table 6  for Cohort 7). 
7.1. Efficacy Assessments  
The PD and biomarker assessments are described in Section  7.6. 
7.1.1. Liver Biopsy and Scoring (Part 2 O nly) 
Liver biopsy remains  the gold standard for diagnosing NASH as well as for establishing the 
degree of liver fibrosis as it can reliably assess the various histopathological patterns 
characteristic of NASH ( Arab, 2018; Bedossa, 2018; Gunn, 2018; Isabela Andronescu, 2018). In 
addition, histopathology scores are used to assess extent of fibrosis before and after treatment. The fibrosis stage ranges from F0 (without fibrosis) to  F4 (cirrhosis).  Currently , liver biopsy is 
required by [CONTACT_9301] a surrogate endpoint to assess drug efficacy in Phase [ADDRESS_8636] dose of study intervention (as specified in the SoA 
(Table 6 ). Details on the biopsy procedure, preparation of slides and central read are provided in 
Protocol BIO 89-100-[ADDRESS_8637]. 
In addition to the central read, liver histology will also be quantitatively assessed by [CONTACT_9302]- based 
machine-read analysis. Additional details  are provided in the Biopsy Manual.  
7.2. Safety Assessments  
Safety assessments include AEs (either reported by [CONTACT_9303]), 
concomitant medication use, physical examination, ECG, vital s igns, and laboratory assessments. 
Planned time points for all safety assessments are provided in the SoAs ( Table  2 for Cohorts 1 -4, 
Table  4 for Cohorts 5-6, and Table  6 for Cohort 7). 
7.2.1. Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the cardiovascular, respi[INVESTIGATOR_696], abdominal and a neurological exam . Height (only  
collected at screening) and weight will also be measured and recorded.  
• A symptom directed  physical examination will include, at a minimum, assessments of 
the skin, respi[INVESTIGATOR_696] , cardiovascular system, and abdomen (liver and spleen). 
7.2.2. Vital Signs  
• Vital signs  include blood pressure, pulse, body temperature, and respi[INVESTIGATOR_697]. 
• Planned time points for vital signs are provided in the SoAs ( Table 2  for Cohorts  1-4, 
Table 4  for Cohorts 5-6, and Table 6  for Cohort 7). 
• Starting from randomization, blood pressure and pulse will be measured in duplicate, the first measurement will be taken up to [ADDRESS_8638]/seated position and resting for at least 5 minutes prior to 
measurements. 
7.2.3. Electrocardiogram s 
• 12-lead ECG will be recorded as single bedside measurements using an ECG machine 
that automatically calculates the heart rate and measures PR, QRS, and QT (QTcF) 
intervals.  
• Subject to be resting for at least 2 minutes prior to ECG . 
7.2.4. Columbia -Suicide Severity Rating Scale (C -SSRS)  
The Columbia Suicide Severity Rating Scale (C -SSRS) is a semi -structured interview that 
assesses suicidal ideation and behaviors ( Posner, 2011) . The C- SSRS can be administered by a 
medical professional (MD, DO, PhD, PA-C, NP, RN) or research coordinator who has 
documented training of the C- SSRS.  
The “Baseline/Screening Version” C -SSRS will be administered at Day -1 (Part 1) or during 
screening (Part 2) to exclude subject s with any past or current suicidal ideations or attempts. 
Subjects will be excluded from the study if they answer “yes” to any one of the suicidal ideation 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 80 
 or suicidal behavior questions. The “Since Last Visit” version will be administered in Part 1 only 
at subsequent visits as specified in the SoAs ( Table  2 for Cohorts 1 -4, Table  4 for Cohorts 5-6 ). 
Any clinically significant change from baseline may be recorded as an AE if deemed appropriate by [CONTACT_9304]. 
7.2.5. Clinical Safety Laboratory Assessments  
See Appendix 2 (Section  9.2) for the list of clinical laboratory tests to be performed and the 
SoAs ( Table 2  for Cohorts 1-4, Table 4  for Cohorts 5-6, and Table  6 for Cohort 7) for the timing 
and frequency. L aboratory tests should be performed under fasting conditions ( ≥10 hours ). 
Fasting includes food and all beverages except for non- mineral water. It is recommended that 
subjects abstain from consumption of alcoholic beverages for at least [ADDRESS_8639] 's condition. 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within [ADDRESS_8640] dose of study intervention  should be repeated until 
the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_9304] ’s Medical Monitor.  
If such values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_3786], the etiology should be identified and the Sponsor notified. 
All protocol -required laboratory assessments, as defined in Appendix 2 (Section  9.2), must be 
conducted in accordance with the relevant study m anual and the SoAs ( Table 2  for Cohorts 1 -4, 
Table 4  for Cohorts 5-6, and Table 6  for Cohort 7). 
If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in subject management or are considered clinically 
significant by [CONTACT_737] (e.g., SAE or AE or skippi[INVESTIGATOR_9229] ), then the results must be 
recorded in the e CRF  and the Sponsor should be notified. 
7.3. Adverse Events and Serious Adverse Events 
The definitions of an AE or SAE can be found in Appendix 3 (Section  9.3). 
AEs will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, or the 
subject 's legally authorized representative).  
The Investigator and any  qualified  designees are responsible for detecting, documenting, and 
recording  events that meet the definition of an AE or SAE and remain responsible for following 
up AEs  that are serious, considered related to the study intervention  or study  procedures, or that 
caused the subject to discontinue the  study or study intervention (s ee Section  6). 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 81 
 7.3.1. Time Period and Frequency for Collecting AE and SAE Information 
All AEs and SAE s will be as specified in the SoAs ( Table  2 for Cohorts 1 -4, Table  4 for 
Cohorts 5-6, and Table  6 for Cohort 7). 
Table [ADDRESS_8641] dose of study intervention  
Reporting Timelines to the Sponsor  Entered into the clinical database on an ongoing basis   Within 24 hours  Within 24 hours  
All SAEs  will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 (Section  9.3). The 
Investigator will submit any updated SAE data to the Sponsor or designee  within [ADDRESS_8642] has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention  or study participation, the Investigator must promptly notify the 
Sponsor or designee. 
7.3.2. Method  of Detecting AE s and SAE s 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 (Section  9.3). 
Care will be taken not to introduce bias when detecting AE s or SAEs . Open -ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrences. 
7.3.3. Follow- up of AE s and SAE s 
After the initial AE  or SAE report, the Investigator is required to proactively follow ea ch subject 
at subsequent visits/contacts. All SAE s, will be followed until resolution, stabilization , the event 
is otherwise explained, or the subject  is lost to follow -up (as defined in Section  6.3). Further 
information on follow -up procedures is given in Appendix 3 (Section 9.3). 
7.3.4. Regulatory Reporting Requirements for SAE s 
• Prompt notification by [CONTACT_9305] s and the safety of a study intervention under clinical investigation are met.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 82 
 • The Sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention  under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards (IRBs)/Independent E thics C ommittees (IECs ), and investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R s) according to local regulatory requirements and Sponsor policy 
and forwarded t o investigators as necessary.  
• An Investigator who receives an Investigator safety report describing a n SAE or other 
specific safety information (e.g., summary or listing of SAE s) from the Sponsor will 
review and then file it along with the IB  and will noti fy the IRB/IEC, if appropriate 
according to local requirements.  
7.3.5. Pregnancy  
• Details of all pregnancies in female subject s and  of female partners of male subject s 
will be collected after the start of study intervention and until [ADDRESS_8643] dose 
of study intervention . 
• If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours 
of learning of the pregnancy and should follow the procedures outlined in 
Appendix 4. 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
7.4. Treatment of Overdose  
There is no experience with overdose of BIO89-100 in humans.  
For this study, any dose of BIO89-100 greater than the protocol-specified dose will be 
considered an overdose. 
The Sponsor does not recommend specific treatment for an overdose. In the event of an overdose, the Investigator should: 
• Contact [CONTACT_9306] . 
• Closely monitor the subject  for any AEs  and laboratory abnormalities until study 
intervention can no longer be detected systemically (at least  30 days). 
• Obtain a plasma sample for PK analysis within 2 days  from the date of the overdose if 
requested by [CONTACT_1689] (determined on a case -by-case basis) . 
• Document the quantity of the excess dose as well as the incidence of the overdose  in 
the e CRF.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 83 
 7.5. Pharmacokinetics  
Blood samples for analysis of BIO89 -100 serum levels will be collected at the timepoints 
designated in the SoAs ( Table  3 for Cohorts 1 -4, Table  5 for Cohorts 5-6, and Table  6 for 
Cohort 7). 
Blood samples will be processed for collection of serum fractions for determination of 
BIO89 -100 serum concentrations. Serum samples will be shipped to the bioanalytical laboratory 
for analysis.  
The trough serum BIO89 -100 concentrations will be summarized by [CONTACT_9307] . 
Pharmacokinetic parameters calculated by [CONTACT_9308]89 -100 
serum concentration data will include: 
PK Parameter  Cohorts [ADDRESS_8644] dosing interval s 
Additional PK parameters may be calculated if deemed appropriate.  
The serum concentration -time data may also be used for population PK modeling with the results 
reported separately from the clinical stu dy report. 
7.6. Pharmacodynamics and Biomarkers  
7.6.1. Immunogenicity Assessments  
Antibodies to BIO89 -100 as well as titer and binding specificity will be evaluated in serum 
samples collected from all subjects at timepoints designated in the SoAs ( Table  2 for 
Cohorts 1-4, Table  4 for Cohorts 5-6, and Table  6 for Cohort 7). Subjects who test positive  
 
 
 
 
 More frequent testing (e.g. every month) or testing for a 
longer period of time may be requested in the event of safety-related concerns. Follow-up testing 
will not be required where it is established that the subject did not receive BIO89 -100. All 
follow -up results, both positive and negative will be communicated to the sites. A blood sample 
for ADA assessment will also be collected upon observation of any severe hypersensitivity reaction (e.g., anaphylaxis). Subjects who test positive  
 
 
Samples for endogenous FGF21 level will be co llected  at baseline for all subjects, and at the 
time of acquisition of the follow -up blood sample (s) for ADA assessment , in  

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 84 
  
  
S
erum samples will be screened for antibodies binding to  BIO89 -100 and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to BIO89 -100 and/or further charac terize the immunogenicity of BIO89 -100. 
The detection and characterization of antibodies to BIO89 -100 will be performed using a 
validated assay method under the supervision of the Sponsor . Antibodies may be further 
characterized and/or evaluated for their ability to neutralize the activity of the study 
intervention(s). Samples may be stored for a maximum of  (or according to local 
regulations) following the last subject’s last visit for the study at a facility selected by [CONTACT_9309]89 -100. 
7.6.2. Pharmacodynamics 
The following biomarkers/PD parameters will be evaluated at timepoints designated in the SoAs (Table  2 for Cohorts 1-4, Table  4 for Cohorts 5-6, and Table  6 for Cohort 7): 
Laboratory P arameters  
• Triglycerides  
• Non-HDL cholesterol 
• HDL -c 
• LDL -c 
• HbA1c  
• HOMA- IR (Part 1 only)  
• Liver function tests: ALT, AST  
• GGT  
• Alkaline phosphatase 
• Adiponectin  
• Pro-C3 (see Section  [IP_ADDRESS]) 
• Free fatty acids  and Adipo- IR (fasting free fatty acids   fasting insulin; Part 1 only ) 
  
   
  
  
  
  

Protocol BIO 89-100-[ADDRESS_8645]’s last visit for the study, 
at a facility selected by [CONTACT_1034], to enable further analysis of biomarker responses to 
BIO89 -100. 
Residual blood samples will be stored for potential future analysis of biomarkers . 
Additional information will be available in the study specific laboratory manual.  
Other parameters include:  
• Imaging measures  (Section  [IP_ADDRESS]) 
− MRI -PDFF  
  
  
  
  
  
• Anthropomorphic measurements  
− Body weight 
   
   
  
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]. Homeostatic Model Assessment for Insulin Resistance (HOMA -IR; Part  1 only) 
HOMA-IR is a method used to quantify insulin resistance based on the following formula (s) 
(Matthews, 1985) : 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 86 
 Glucose in mmol/L   Glucose in mg/dL  
HOMA- IR = Glucose × Insulin   HOMA- IR = Glucose × Insulin  
22.5  405 
  
 
 
 
 
[IP_ADDRESS].
 N-terminal Propeptide of Type III Collagen (Pro- C3) 
N-protease cleaved N -terminal prope ptide of type 3 procollagen (P3NP) neo-epi[INVESTIGATOR_9230] (Pro- C3) is 
derived from the synthesis of type [ADDRESS_8646] and as part of algorithms  
(Nielsen, 2015; Daniels, 2018; Hansen, 2018) . 
[IP_ADDRESS]. Magnetic Resonance Imaging – Whole L iver Proton Density Fat Fraction 
(MRI -PDFF)   
MRI -PDFF is as a noninvasive, quantitative, and accurate measure of liver fat content (imaging -
based biomarker) to assess treatment response in NASH clinical studies (Caussy, 2018) . 
This technology enables post- processing of MRI data into parametric map of PDFF (Antaros 
Medical, Sweden)  to provide accurate and quantitat ive measures of liver fat.  
 
 
 
 
 
 
 
 
 
PD
FF 
The PDFF is determined using a [ADDRESS_8647] ies multi -peak lipid spectral models and  
simultane ous quantification and correction for T2*. The liver fat value  (PDFF)  is the me an value 
of all voxels in the identified volume of interest .  
For more information, refer to the Imaging Manual.  

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 87 
 7.6.3. Exploratory Analyses 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 88 
 8. STATISTICAL CONSIDERATIONS  
This section describes the statistical analysis  as foreseen at the time of planning the study. 
Changes, additions, and further details about the analyses will be described in the statistical 
analysis plan, if applicable. Any subsequent additional analyses or changes to analyses that may be required wil l be fully disclosed in the clinical study report. Summaries and analyses will be 
presented by [CONTACT_2715]/treatment group for Part 1 and separately for Part 2 . Before database lock, 
final statistical and pharmacokinetic analysis plans containing full details of all planned analyses will be produced. The analyses presented here represent an outline of the intended methodology. 
Details of the analysis will be described in a Statistical Analysis Plan. All clinical data will be 
summarized using descriptive statistics : number (n), mean, standard deviation ( SD), median, 
minimum, and maximum for continuous measurements, and counts and percentages for 
categorical measurements.  
8.1. Statistical Hypotheses  
The Part [ADDRESS_8648] of BIO89 -100 on selected PD markers and 
biomarkers  will be assessed by [CONTACT_9310],  90% confidence intervals and the descriptive 
p-values of mean changes/percentages changes from baseline within and between treatment 
group. 
For Pa rt 2, the primary objectives are to evaluate incidence of AE s and to assess histological 
response of BIO89-100 in the NASH population. 
8.2. Sample Size Determination  
For Part 1, n o formal sample size calculation was performed  for the primary endpoint(s) as the  
total of approximately 83  subjects, consisting of 6:2  (Cohort 1) , 12:3  (Cohort 2), 9:3 (Cohorts 4 
and 6), or 14 :4 (Cohorts 3 and 5) receiving active  : placebo, respectively  is considered adequate 
for Part [ADDRESS_8649] with one-sided 5% (e.g., two -sided 10%) type I error probability.  
Subjects who withdraw from the study before the Day [ADDRESS_8650]-baseline liver biopsy (e.g.,  to have paired liver biopsies). With a sample size of , the 95% confidence interval of the histological response rate would 

Protocol BIO 89-100-[ADDRESS_8651] a half -width no greater than  assuming the histological response  The 
actual half -width will depend on the observed histological response rate. 
8.3. Populations for Analyses  
For purposes of analysis, the following populations are defined: 
Population  Description  
Screened Analysis set  All enrolled subjects who signed informed consent and undergone screening. 
Part [ADDRESS_8652]-baseline PD 
data; subjects will summarized based on the randomized treatment group . 
Different PD analysis set s may be used for different type s of PD endpoints, 
e.g., MRI-PDFF. 
Part [ADDRESS_8653] -baseline biopsies.  
8.4. Statistical Analyses  
The statistical analysis plan (SAP) will be developed and finalized before database lock and will 
describe the subject populations to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. Pooling of placebo subjects in Part [ADDRESS_8654] ives, the 
evaluation of potential efficacy will be determined based on the totality and pattern of data from the biomarker and PD endpoints. The assessment of biomarker and PD endpoints will employ 
90% confidence intervals and significance testing for assessing within group changes and percentage changes from baseline and comparisons of the BIO89 -100 doses to the pooled 
placebo group. Details will be provided in the SAP. 
The correlation  between relevant PK parameters and PD endpoints will be examined  as wil l be 
detailed in the SAP. 
Subjects with dose interruptions impacted by [CONTACT_9311]- 19 pandemic will be  noted in the  
listings. Subgroups including and excluding subjects with dose interruptions due to COVID-19 
pandemic may  be considered  for both efficacy and safety analyses as appropriate.  
For Part 2, endpoints of different histological response s will be summarized  with the point 
estimates and 95% confidence intervals of the proportions of subjects who meet the response criteria using the biopsy analysis set. 
8.4.1. Safety and Tolerability Analyses 
All safety analyses will be performed on the Safety Analysis Set  in Part 1 and Full Analysis Set 
in Part 2 . The safety assessment will be based on AEs, laboratory values, concomitant 
medication use, ECG, vital signs,  and physical examination. Summaries will be presented by 
[CONTACT_3148]/dose.  
All adverse events will be coded using the Medical Dictionary for Regulatory Activities (current  
version of MedDRA) . The severity of adverse events will be graded according to the current 
version of National Cancer Institute ( NCI) common terminology criteria for adverse events 
(CTCAE ) v5. All AE  summaries will include treatment-emergent adverse events (TEAEs), 
defined as those which occur after the first dose of study intervention (BIO89 -100 or placebo). 
Treatment -related AEs  are those which were determined by [CONTACT_9312]. The incidence of treatment -related AEs (as recorded in the e CRF) will be 
summarized using descriptive statistics by [CONTACT_9313] (SOC) and preferred term, 
categorized by [CONTACT_9314]. Counting will be done for each subject (subjects 
will only be counted once within each SOC or preferred term). The frequency of TEAE  (AE 
burden) will be summarized using descriptive statistics by [CONTACT_9315] (PT). 
Counting will be done for events (regardless of subjects), by [CONTACT_3592]. The incidence of TEAE will also be presented by [CONTACT_9316]-dose, SOC, PT, and severity. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 91 
 A listing of TEAEs  and TEAEs  leading to study discontinuation will be provided. Summ aries 
will be presented by [CONTACT_2715]/treatment group. Subject listings of SAEs  and AE  leading to 
withdrawal will be presented. Actual values and changes in laboratory (serum chemistry, 
hematology, coagulation, and urinalysis), ECG, and vital signs measurements including weight data will be summarized descriptively. Laboratory data will also be presented by [CONTACT_9317] 
(severity) scale according to the current version of NCI CTCAE for each time point recorded. All 
values will be compared with  prespecified boundaries to identify potentially clinically significant 
values or changes, as detailed in the statistical analysis plan, and such values will be listed. All 
prior and concomitant medications will be coded using the World Health Organization drug 
dictionary (WHO Drug) and will be listed. Concomitant medications will include all medications taken from first dose through to the EOS visit. If any subject dies during the study, a listing of 
deaths will be provided and all relevant information will be discussed in the sub ject narrative 
included in the clinical study report. The relationship of overall safety with respect to 
pharmacokinetics, immunogenicity assessments, and prespecified exploratory biomarkers will be 
evaluated, as appropriate. 
The number (%) of subjects who fail to complete the study and the reason for discontinuation, 
and the number (%) of subjects who fail to complete the study due to related adverse events will 
be summarized.  
8.4.2. PK Analyses 
All PK population subjects will be included in the PK analysis.  
Pharmacokinetic parameters including but not limited to those listed in Section 7.[ADDRESS_8655] and summarized by [CONTACT_9318] 
(sample size, mean, median, geometric mean [as appropriate], coefficient of variation [CV%], 
SD, minimum, and maximum) for continuous variables and using frequencies and percentages 
for discrete variables.  
Serum concentration data will be listed by [CONTACT_9319]. 
Serum concentration by [CONTACT_9320] w ill be presented graphically. Mean serum 
concentration by [CONTACT_9321]. Further details on PK analysis will 
be provided in the SAP. 
8.4.3. Immunogenicity  Analyses 
Results of immunogenicity assessment will be provided by [CONTACT_9322] ( e.g., number and 
percent of positive ADA subjects) and immunogenicity profile (e.g., antibody titers, binding 
specificity , and neutralizing immunogenicity ), when appropriate. 
The effect of ADA on relevant PK parameters may be evaluated.  
For endogenous FGF21 , baseline samples will be analyzed; sample(s) will also be obtained fr om 
 subject with additional follow -up visit(s) for potential future analysis  to 
evaluate effect of ADA on  endogenous FGF21 level. 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 92 
   
 
 
 
8.5. Interim Analyses  
No efficacy  interim analysis is planned.  The Sponsor may perform administrative interim 
analysis to support objectives such as study planning and regulatory interaction.  
8.6. Safety Monitoring Committee (SMC) 
The SMC , a specific committee for the study composed of the Sponsor’s Medical Monitor , the 
CRO Medical Monitor , and at least one participating Investigator, will only function in Part 1 , as 
described in Section  3.2. The operations of the SMC will be defined in the SMC Charter.  
Given the open-label design of Part 2, safety will be reviewed  on an ongoing basis by [CONTACT_9323]/or CRO Medical Monitor s. 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 93 
 9. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
9.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
9.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
− Consensus ethic al principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
− Applicable ICH Good C linical P ractice (GCP) Guidelines 
− Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator ’s Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_6661]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB /IEC approval before 
implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subjects. 
• The Investigator will be  responsible for  the following : 
− Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/ IEC 
− Notifying the IRB/IEC of SAE s or othe r significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if  applicable), and all 
other applicable local regulations  
9.1.2. Financial Disclosure  
Investigators and sub- investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
9.1.3. Informed Consent Process  
• The Investigator or his  or her representative will explain the nature of the study to the 
subject or his or her legally authorized representative and answer all questions 
regarding the study. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 94 
 • Subject s must be informed tha t their participation is voluntary. Subject s will be 
required to sign a statement of informed consent that meets the requirements of 
[ADDRESS_8656] ( HIPAA) requirements , whe re applicable, and the IRB/IEC or 
study center.  
• The medical record must include a statement that written informed consent was obtained before the subject  was enrolled in the study and the date the written consent 
was obtained. The authorized person obtaining the informed consent must also sign 
the ICF.  
• Subject s must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the subject  or the subject ’s legally 
authorized repres entative.  
Subject s who are rescreened are required to sign a new ICF.  
9.1.4. Data Protection 
• Subjects will be assigned a unique identifier by [CONTACT_1034]. Any subject  records or 
datasets that are transferred to the Sponsor will contain the identifier only; subject 
names or any information which would make the subject identifiable will not be transferred.  
• The subject must be informed that his  or her personal study- related data will be used 
by [CONTACT_9324]. The level of disclosure must also be explained to the subject . 
• The subject must be informed that his/her medical records may be examined by 
[CONTACT_9325], by [CONTACT_6667]/IEC members, and by [CONTACT_9326]. 
9.1.5. Dissemination of Clinical Study Data  
A clinical study report will be developed by [CONTACT_9327]. This 
report will be a clinical and statistical integrated report, according to the ICH E3 guidelines.  
Sponsor will register the study and post study results regardless of outcome on a publicly 
accessible website in accordance with the applicable law s and regulations. 
9.1.6. Data Quality Assurance 
• All subject data relating to the study will be recorded on the e CRF s unless transmitted 
to the Sponsor or designee electronically (e.g., laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_9328] e CRF.  
• The Investigator must maintain accurate documentation (source data) that supports 
the information entered in  the e CRF.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 95 
 • The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on- site 
monitoring) are provided in the Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (e .g., 
Contract Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of subjects are being 
protected; a nd that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. It may become required that some or all monitoring 
activities will be halted or performed remotely  due to the recent COVID-19 
pandemic . In such a case, details of the changes made to the monitoring strategy will 
be described  in the Monitoring Plan.  
• Records and documents, including signed ICFs, pertaining to the conduct of this 
study mus t be retained by [CONTACT_9329] -GCP and local regulations or 
institutional policies. No records may be destroyed during the retention period 
without the written approval of the Sponsor. No records may be transferred to another 
location or party w ithout written notification to the Sponsor, whether within the 
retention period or thereafter. 
9.1.7. Source Documents  
• Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are fi led at the Investigator ’s 
site. 
• Data entered in the eCRF that  are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, 
depending on the study. A lso, current medical records must be available.  
• Source documents are original documents, data, and records from which the subject ’s 
eCRF data are obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence. 
9.1.8. Study and Site Closure  
The Sponsor designee reserves the right to close the study sit e or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
Protocol BIO 89-100-[ADDRESS_8657] been collected and a study- site closure visit has been performed . 
The Investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given to the Sponsor  in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_9330]: 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recrui tment of subjects by [CONTACT_737]  
• Discontinuation of further study intervention  development 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator shall promptly inform the subject  and 
should assure appropriate subject therapy and/or follow -up. 
9.1.9. Publication Policy  
• The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows the Sponsor to pro tect proprietary 
information and to provide comments. 
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator [INVESTIGATOR_9231].  
• Authorship will be determined by [CONTACT_9331]. 
  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 97 
 9.2. Appendix 2: Clinical Laboratory Tests 
• The clinical laboratory tests detailed in  Table 9  will be performed by a central 
laboratory , except if noted otherwise, at timing/frequency detailed in the SoAs 
(Table  2 for Cohorts 1-4, Table  4 for Cohorts 5-6, and Table  6 for Cohort 7). 
Laboratory tests will be performed under fasting conditions (≥10 hours ). 
• Protocol- specific requirements for inclusion or exclusion of subject s are detailed in 
Section  3.3 and Section 4.3 of the protocol for Parts 1 and 2, respectively .  
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_9332].  
Table  9 Protocol- Required Laboratory Assessments  
Hematology   
White blood ce ll count (WBC) with differential 
(Neutrophils , Lymphocytes , Monocytes , 
Eosinophils , Basophils  – absolute and %) Red blood cell ( RBC) 
RBC Indices : 
MCV , MCH , %Reticulocytes  
Hemoglobin Hematocrit  
Platelet count Coagulation factors, including PT, INR, aPTT  
Red cell Distribution W idth 
Clinical Chemistries   
Alanine Aminotransferase (ALT)  Aspartate Aminotransferase ( AST)  
Alkaline phosphatase  (ALP)  Gamma-glutamyl transferase (GGT)  
Total bilirubin, Indirect/direct bilirubin  Albumin  
Calcium  Blood urea nitrogen (BUN)  
Sodium  Creatinine  
Chloride  Creatine Kinase  
Magnesium  Bicarbonate  
Potassium  Lactate dehydrogenase 
Phosphorus/  Total protein  
Glucose (fasting)  Total Cholesterol 
Triglycerides  Uric Acid  
High -density lipoprotein cholesterol (HDL -c) 
Low density lipoprotein (LDL -c) 
Non-high- density lipoprotein cholesterol (non-
HDL -c) 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 98 
 Urinalysis   
Basic Urinalysis (dipstick, including macroscopic 
appearance, bilirubin, blood, color, glucose,  
ketones, leukocyte esterase, nitrite, pH, protein,  
specific gravity, urobilinogen ;  Full urinalysis (dipstick plus microscopic 
evaluation)  to be performed only at the Screening 
and End of  Study visits ). A reflex microscopic 
urinalysis should be performed if the results of the urinalysis is abnormal or at the discretion of the PI [INVESTIGATOR_9232].  
Other  Study -Specific  Laboratory Assessments   
BIO89-100 (to be evaluated by [CONTACT_9333])  Insulina 
High -sensitivity C -reactive protein (hsCRP)a 
Oral glucose tolerance test (OGTT) including 
C-peptide, glucose, and insulina 
Hemoglobin A1c (HbA1c)  
Homeostatic model assessment of insulin resistance (HOMA-IR)
a 
Insulin -like growth factor -1 (IGF -1), t otala 
Adiponectin, total 
Cytokeratin (CK) -18a 
Enhanced liver fibrosis (ELF) panela 
N-terminal propeptide of type III collagen 
(Pro-C3)  
Fasting free fatty acids and Adipo-IR (fasting 
FFA x fasting insulin)a 
 Serum and urine human chorionic gonadotropin 
(hCG) p regnancy test  
TSH  
FSH ( only for determination of postmenopausal 
status)  
Urine drug screen including  amphetamines, 
barbiturates, cocaine metabolites, opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_9233]  (on Day -1, can 
done at  local laboratory , but must also collect 
sample for central laboratory).  
Virology - HIV antibody, hepatitis B surface 
antigen (HBsAg, and hepatitis C virus antibody) 
24-hour urine for cortisol
a 
Immunogenicity : 
Antibody to BIO89-100  
Endogenous FGF21  
Bone markers  - carboxy-terminal collagen 
crosslinks (CTX) , N-terminal propeptide of type 1 
collagen (P1NP), osteocalcin   
Plasma and serum samples for exploratory 
biomarkersa 
DNA and RNA samplesa 
a-Part 1 only ; all other tests are done in both Parts [ADDRESS_8658] document their review of each laboratory safety report.  
 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 99 
 9.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting 
9.3.1. Definition of AE  
AE Definition 
• An AE is any untoward medical occurrence in a clinical study subject , temporally associated with 
the use of study intervention, whether or not considered related to the study intervention.  
• NOTE: An AE can, therefore, be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or uri nalysis) or other safety 
assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator  (i.e., not related to pr ogression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant  medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self- harming intent. Such overdoses should be 
reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by [CONTACT_9334]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject ’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): th e condition that leads to the 
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 100 
 9.3.2. Definition of Suspected and Unsuspected Adverse Reaction  
Suspected adverse reactions are defined as:  
• Any AE for which there is a reasonable possibility that the study intervention caused the AE. For 
the purposes of sponsor regulatory safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the study intervention and the AE. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any AE caused by a study intervention  
Unexpected AEs are defined as:  
• AE which is not listed in the IB of the study intervention or is not listed at the specificity or severity that has been observed  
9.3.3. Definit ion of Events to Monitor  
Sponsor -defined Events to Monitor  for BIO89 -100: 
Events to Monitor  include hypersensitivity reactions occurring after the first administration of study 
agent(s) in subjects participating in this clinical study. These events must b e reported by [CONTACT_9335] 24 hours  and are to be considered serious (for regulatory reporting 
purposes) only if they meet the definition of a n SAE . The events are to be reported on an SAE  form  
9.3.4. Definition of SAE  
If an event is not an AE per definition in Section 9.3.1, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose:  
1. Results in death 
2. Is life-threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe.  
3. Requires inpatient hospi[INVESTIGATOR_9234], hospi[INVESTIGATOR_5184] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline i s 
not considered an AE.  
4. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
Protocol BIO 89-100-[ADDRESS_8659] medical occurrence that, at any dose:  
(e.g., sprained ankle) which may interfere with or prevent everyday  life functions but do not 
constitute a substantial disruption.  
5. Is a congenital anomaly/birth defect  
6. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as importa nt medical events that may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_9237]. These e vents should usually be considered serious.  
• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.  
9.3.5. Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all documentation 
(e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE information in the eCRF. 
• It is not acceptable for the Investigator  to send  photocopi[INVESTIGATOR_9238]’s medical records to the 
Medical Monitor in lieu of completion of the AE/SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_9239]. In this case, all subject  identifiers, with the exception of the subject  number, 
will be redacted on the copi[INVESTIGATOR_9240].  
• The Investigator  will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The severity of each AE will be assessed at onset by a nurse and/or physician. When recording the 
outcome of the AE the maximum severity of the AE experienced will also be recorded. The severity of 
the AE will be graded according to the CTCAE v5.0:  
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. 
Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate 
instrumental Activities of Daily Living (ADL)*. 
Grade 3: Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_9241]; disabling; limiting self -care ADL**.  
Grade 4: Life -threatening consequences; urgent intervention indicated.  
Grade 5: Death related to AE.  
ADL:  
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and 
not bedridden.  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 102 
 AE and SAE Recording  
Assessment of Causality  
The Investigator  is obligated to assess the relationship between study intervention and each occurrence 
of each AE/SAE.  
• A “"reasonable possibility”" of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event t o study intervention administration will be 
considered and investigated. 
• The Investigator  will also consult the Investigator’s Brochure (IB) and/or Product Information, 
for marketed products, in his/her assessment.  
• For each AE/SAE, the Investigator  must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Medical M onitor. However, it is very 
important that the Investigator  always make an assessment of causality for every event 
before the initial transmission of the SAE data to the Medical Monitor.  
• The Investigator  may change his/her opi[INVESTIGATOR_9242] -up information and 
send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Causality Categories:  
• UNRELATED - This relationship suggests that there is no association between the study drug 
and the reported event.  
• UNLIKELY RELATED - The relationship suggests that the event is more likely due to other 
causes than study drug, however the  relationship to the study drug cannot be ruled out.  
• POSSIBLY RELATED - This relationship is based on evidence suggesting a causal 
relationship between the study drug and the AE, i .e., there is a reasonable possibility that the 
drug caused the event. The event follows a reasonable temporal sequence from the time of drug 
administration or follows a known response pattern to the study drug but could also have been 
produced by [CONTACT_1604].  
• PROBABLY RELATED - This relationship suggests that a reasonable temporal sequence of 
the event with drug administration exists and, based upon the known pharmacological action of the drug, known or previously reported adverse reactions to the drug or class of drugs, or judgment based on the Investigator’s clinical experienc e, the association of the event with the 
study drug seems likely.  
• DEFINITELY RELATED - This relationship suggests that a definite causal relationship exists 
between drug administration and the AE, and other conditions (concurrent illness, progression/expre ssion of disease state, or concurrent medication reaction) do not appear to 
explain the event.  
 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 103 
 Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_9336]/or causality of the AE or SAE as fully as possible. This may inclu de 
additional laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals. 
• If a subject  dies during participation in the study or during a recognized follow -up period, the 
Investigator  will provide the Medical Monitor with a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed eCRF. 
• The Investigator  will submit any updated SAE data to the Sponsor within 24 hours of receipt of 
the information.  
9.3.6. Reporting of SAEs  
Reporting of SAEs will be done using eCRF (with paper methods as a back-up in case of system 
unavailability). 
SAE Reporting to the Medical Monitor via an Electronic Data Collection (eCRF) Tool 
• The primary mechanism for reporting an SAE to the Medical Monitor will be the electronic data 
collection tool. 
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool 
(see next section) in order to report the event within 24 hours.).  
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off -
line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study subject  or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off -line, then the 
site can report this informati on on a paper SAE form (see next section) or to the Medical Monitor 
by [CONTACT_756].  
• Contacts for SAE reporting can be found in the  relevant manual.  
 
SAE Reporting to the Medical Monitor via Paper CRF  
• Facsimile or email  transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Medical Monitor , 
• In rare circumstances and in the absence of facsimile or email equipment, notification by [CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_9338] o r 
courier service.  
• Initial notification via telephone does not replace the need for the Investigator  to complete and 
sign the SAE CRF pages within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the  relevant manual. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 104 
 9.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered  fertile following menarche and until becoming post-menopausal unless 
permanently sterile  (see below) . 
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following cate gories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with one of the following:  
− hysterectomy  
− bilateral salpi[INVESTIGATOR_1656]  
− bilateral oophorectomy  
• For individuals with permanent i nfertility due to an alternate medical cause other than 
the above, (e.g., Mullerian agenesis, androgen insensitivity), Investigator discretion 
should be applied to determining study entry. 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
− A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However , in the absence o f 12 months of 
amenorrhea, confirmation with more than one FSH measurement is required. 
− Females on HRT and whose menopausal status is in doubt will be required to use one of the non -estrogen  hormonal highly effective contraception methods if they 
wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before  study enrollment. 
Male subjects with a female partner who is not of childbearing potential  
Presumptive fertile male subjects who are partnered with women who are not of childbearing potential, either post-menopausal or through sterilization or other surgical procedures (e.g., hysterectomy) will confirm that their partners have been determined to be sterile or post-
menopausal based on medical judgment; this can be confirmed either by [CONTACT_9339], if presented by [CONTACT_423]. 
Men will not be required to use other contraception when sexually active with a sterile or post -
menopausal partner.  
Men who are sexually active w ith fertile women need to confirm that they will use 2 forms of 
contraception as per protocol. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 105 
 Contracept ion Guidance : 
Contraceptive use by [CONTACT_9340].  
Subjects should use highly effective, double contraception (both male and female partners) 
during the study and 30 days or 5 half- lives (whichever is longer) of study intervention . 
Double contraception is defined as a condom with one of any of the following forms of birth 
control: 
• Birth control pi[INVESTIGATOR_3353] (The Pi[INVESTIGATOR_4382])  
• Depot or injectable birth control  
• Intrauterine Device (IUD) 
• Birth Control Patch (e.g., Othro Evra)  
• NuvaRing® 
• vasectomy for men  
Subjects may not donate sperm or oocytes during the study and for 30 days or 5 half- lives 
(whichever is longer) after last dose of study intervention. 
Rhythm methods are not considered as highly effective methods of birth control. Subject 
abstinence for the duration of the study and 30 days or 5 half- lives (whichever is longer) after 
last dose of study intervention is acceptable if it is the subject’s regular practice. 
Collection of Pregnancy Information Male subject s with partners who become pregnant  
• The Investigator will attempt to collec t pregnancy information on any male subject’s 
female partner who becomes pregnant while the male subject is in this study. This 
applies only to male subject s who receive study intervention . 
• After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the 
estimated de livery date. Any termination of the pregnancy will be reported regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.  
Female s ubjects who become pregnant  
• Female subjects who become pregnant should discontinue treatme nt and be 
withdrawn from the study . 
• The Investigator will collect pregnancy information on any female subject who becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the Sponsor within [ADDRESS_8660]'s pregnancy. This applies only to female  subject s who receive study 
intervention 
• The subject will be followed to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the subject  and the neonate and the 
information will be forwarded to the Sponsor. Generally, follow-up will not be 
required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presenc e or 
absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported 
as such. Any post-study pregnancy related SAE considered reasonably related to the 
study intervention by [CONTACT_9341]  7.3.4. While the Investigator is not obligated to actively seek this information 
in former study subjects, he or she may learn of an SAE through spontaneous reporting. 
  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 107 
 9.5. Appendix 5: Considerations in Response to Coronavirus Disease 
2019 (COVID -19) Pandemic   
As of March 12, 2020, a COVID-[ADDRESS_8661] of Clinical Trials of Medical Products during COVID-19 Pandemic ( FDA, July 2020) , the following actio ns were 
implemented to address potential disruptions to study conduct secondary to COVID-19 infection 
or control measures:  
• Interruption in study intervention administration and other study procedures 
(collectively “study interruption”) will be allowed for up to 4 weeks (+4 days). Any interruption lasting ≥  2 weeks will be considered a study interruption. 
• For subjects who have a study interruption, prior to resuming dosing, the Investigator 
will assess whether the subject is clinically stable to continue participation in the 
study. This assessment will include symptom -directed physical examination, vital 
signs, pregnancy test (local) in WOCBP, and laboratory tests (hematology and 
clinical biochemistry) to be done locally.  
If clinical laboratory tests are not part of the protocol- defined procedures for the first dosing 
visit after study interruption, hematology and clinical biochemistry panels will be obtained 
prior to dosing and sent to the central lab. 
 
Results from both the local and central labs should be documented in EDC.  
• Upon resumption of dosing, the subject will continue at the next planned visit re lative 
to the last visit performed prior to study interruption, and will be administered all 
remaining planned doses.  
• Administration of study intervention by a trained home health care worker will be 
considered on a case -by-case basis if circumstances rel ated to the COVID -19 
pandemic preclude dosing at the study site  
• In cases where a subject is continuing to receive study intervention but COVID-19 
pandemic- related circumstances preclude a visit to the investigative site, remote visits 
(e.g., by [CONTACT_9342]) will be allowed for relevant study procedures.   
• In cases where a subject is continuing to receive study intervention but cannot obtain laboratory tests at the investigative site, local laboratory tests  may be obtained at a 
certified l aboratory. The site should inform the Sponsor about such cases. Local 
analysis can be used for safety decisions. In addition, local labs can be used for trial endpoints if samples drawn at the local lab  cannot be shipped to the central lab.   
• (For Part 1 o nly) The Investigator should discuss with the Sponsor on a case-by- case 
basis if circumstances related to the COVID -19 pandemic preclude domiciling around 
the 5
th dose (in Cohorts 3 and 4) or the 3rd dose (in Cohorts 5 and 6); with Sponsor 
approval, these visits may be conducted without domiciling. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 108 
 • (For Part 1 only) As MRI facilities may be impacted by [CONTACT_9343]-[ADDRESS_8662] not yet undergone D ay 50 and Day 92/ET MRI assessments will 
undergo Fibroscan assessments on D ay 50 and D ay 92/ET in addition to the planned 
MRI assessments.  
• End of Treatment may be considered for the following scenarios: 
− For subjects in Part [ADDRESS_8663] reached the Day 57 visit (Visit 17) and subjects in 
Part [ADDRESS_8664] reached the Day 106 visit (Visit 18), an End of Treatment visit 
may be considered instead of the study interruption. The Investigator should 
discuss with the Sponsor about the feasibility of these two options based on the potential impact from COVID -19 and/or the control measures in place in their 
location. 
− Study interruptions longer than [ADDRESS_8665]’s participation in the study.   
Efforts should be made to obtain End of Treatment assessments in subjects who are not willing to return to the study after study interruption, who are deemed not clinically stable to continue participation by [CONTACT_737], or who are lost to the study due to disruptions 
because of COVID -19 pandemic. The End of Treatment visit should be scheduled as soon as 
possible in these scenarios, whenever possible.  
• For dose interruptions lasting ≥[ADDRESS_8666] remotely (e.g., by [CONTACT_9344]) to obtain information about AEs, 
concomitant medications, or any other update related to the subjects’ safety. 
• Study interruption will be allowed as long as COVID-19 pandemic- related 
circumstances are ongoing, and will not be allowed when these circumstances are no 
longer applicable, as determined by [CONTACT_1034]. 
• For newly randomized subjects who have not yet received their first dose at a site that 
can foresee near -term disruption by [CONTACT_4113]-[ADDRESS_8667] will initiate and finish 
all planned doses when the Investigator deems it is safe to start dosing. 
Changes in study visit schedules, missed visits, or patient discontinuations may lead to missing 
information (e.g., for protocol-specified procedures). Specific information will be captured in the 
case report form that explains the basis of the missing data, including the relationship to 
COVI D-19 for missing protocol-specified information (e.g., from missed study visits or study 
discontinuations due to COVID-19). 
  
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 109 
 9.6. Appendix 6: Glossary 
Abbreviation Term  Description  
AAA  Abdominal aortic aneurysm  
ADA  Antidrug Antibodies  
ADL  Activities of Daily Living  
AE Adverse events  
AI Artificial intelligence  
ALP  Alkaline phosphatase  
ALT  Alanine transaminase  
AST  Aspartate transaminase  
AUC 0-tau Area under the serum drug concentration by [CONTACT_9253] a dosing 
interval  
BMD Bone mineral density  
BMI Body mass index  
BUN  Blood urea nitrogen  
CAD  Coronary artery disease  
CAP  Controlled Attenuation Parameter  
CBC  Complete blood count  
CFR Code of Federal Regulations  
CHF  Congestive heart failure  
CIOMS International Organizations of Medical Sciences  
CK Cytokeratin  
Cmax  Maximal observed serum concentrations  
COVID -[ADDRESS_8668]  
HIV Human Immunodeficiency Virus  
HOMA-IR Method used to quantify insulin resistance  
HRT  Hormonal replacement therapy  
hsCRP High sensitivity C -reactive protein  
IB Investigator’s brochure  
ICF Informed consent form  
ICH Council for Harmonisation  
IEC Independent Ethics Committee  
IGF-[ADDRESS_8669]  
OTC  Over -the-counter  
PBC Primary biliary cirrhosis  
P1NP  N-terminal propeptide of type 1 collagen  
PD Pharmacodynamic  
PDFF Proton density fat fraction  
PEG  Polyethylene glycol  
Pro-C3 N‐terminal propeptide of type III collagen  
PK Pharmacokinetic  
PSC Primary sclerosing cholangitis  
PT Preferred term  
PVD  Peripheral vascular disease  
QW Weekly  
Q2W  Every [ADDRESS_8670]  Upper limit of normal  
US [LOCATION_002]  
VAT  Visceral abdominal fat  
VCTE  Vibration -controlled transient elastography  
WBC Blood cell count  
WOCBP Woman of Childbearing Potential  
  
Protocol BIO 89-100-002 
 
89bio Confidential Page 113 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 114 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 115 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 116 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 117 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 118 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 119 
 

Protocol BIO 89-100-002 
 
89bio Confidential Page 120 
 

Protocol BIO 89-100-002 
 
 
89bio Confidential Page 121 
 10. REFERENCES  
Akero  website. https://akerotx.com/efruxifermin/. Accessed 13Oct2 020. 
Arab, J. P., Barrera, F. and Arrese, M. (2018). "The Evolving Role of Liver Biopsy in Non-
alcoholic Fatty Liver Disease." Ann Hepatol 17(6): 899-902. 
Arner, P., Pettersson, A., Mitchell, P. J., Dunbar, J. D., Kharitonenkov, A. and Ryden, M. (2008). 
"FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin 
sensitivity." FEBS Lett 582(12): 1725-1730. 
Bedossa, P. (2018). "Diagnosis of non- alcoholic fatty liver disease/non -alcoholic steatohepatitis: 
Why liver biopsy is essential." Liver Int [ADDRESS_8671] 1: 64-66. Boyum, J.H., Atwell T.D., Schmit, G.D., Poterucha, J.J., Schleck, C.D., Harmsen, W.S., et al . 
(2016). "Incidence and risk factors for adverse evenets related to image-guided liver biopsy." 
Mayo Clin Proc  91: 329-335. 
By[CONTACT_7943], C. D. and Targher, G. (2015). "NAFLD: a multisystem disease." J Hepatol 62([ADDRESS_8672]): 
S47-64. 
Caussy, C., Reeder, S. B., Sirlin, C. B. and Loomba, R. (2018). "Noninvasive, Quantitative Assessment of Liver Fat by [CONTACT_9268] -PDFF as an Endpo int in NASH Trials." Hepatology 68(2): 763-
772. 
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., et al. (2018). "The 
diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Associati on for the Study of Liver Diseases." Hepatology 67(1): 328-357. 
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., et al. (2012). "The diagnosis and management of non- alcoholic fatty liver disease: Practice guideline by [CONTACT_9345], American Association for the Study of Liver 
Diseases, and American College of Gastroenterology."  142. 
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., et al. (2018). 
"ADAPT: An al gorithm incorporating PRO -C3 accurately identifies patients with NAFLD and 
advanced fibrosis." Hepatology. 
Estes, C., Razavi, H., Loomba, R., Younossi, Z. and Sanyal, A. J. (2018). "Modeling the 
epi[INVESTIGATOR_9243]." Hepatology 67(1): 123-133. 
FDA ( July 2020). FDA Guidance on Conduct of Clinical Trials of Medical Products during 
COVID- 19 Pandemic – Guidance for Industry, Investigators and Institutional Review Boards.  
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug 
Evaluation and Research (CDER). from https://www.fda.gov/media/136238/download. 
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. and Sanyal, A. J. (2018). "Mechanisms 
of NAFLD development and therapeutic strategies." Nat Med 24(7): 908-922. 
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., et al. (2013). "The 
effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes." Cell 
Metab 18(3): 333-340. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 122 
 Garcia -Tsao, G. and Boyer, J.L. (1993). "Outpatient liver biopsy: how safe is it?" Ann Intern 
Med 118: 150 -153. 
Gunn, N. T. and Shiffman, M. L. (2018). "The Use of Liver Biopsy in Nonalcoholic Fatty Liver 
Disease: When to Biopsy and in Whom." Clin Liver Dis 22(1): 109-119. 
Hansen, J. F., Juul Nielsen, M., Nyström, K., Leeming, D. J., Lagging, M., Norkrans, G., et al. 
(2018). "PRO- C3: a new and more precise collagen marker for liver fibrosis in patients with 
chronic hepatitis C." Scandinavian Journal of Gastroenterology 53(1): 83-87. 
Harrison, S., Guy, C., Bashir, M. and Alkhouri, N. (2018a). "In a Placebo-Controlled 36- Week 
Phase 2 Trial, Treatment with MGL -3196 Compared to Placebo Results in Signiﬁcant 
Reductions in Hepatic Fat (MRI -PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic 
Lipi[INVESTIGATOR_805], and Improvement in Nash on Serial Liver Biopsy." Hepatology 68(S14). 
Harrison, S., Guy, C., Taub, R., and Basir, M. (2019). " MRI -PDFF response to MGL -3196 and 
placebo treated patients predicts reduction in ballooning and inflammation components of NAS 
and NASH resolution in a 36-week serial liver biopsy study." European Association for the 
Study of the Liver (EASL) abstract.  
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., 
et al. (2018b). "NGM282 for treatment of non- alcoholic steatohepatitis: a multicentre, 
randomised, double-blind, placebo-controlled, phase 2 trial." Lancet 3 91([ZIP_CODE]): 1174-1185. 
Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K., et al. (2009). "Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis." J Gastroenterol [ADDRESS_8673] 19: 89-95. 
Isabela Andronescu , C., Roxana Purcarea, M. and Aurel Babes, P. (2018). "The role of 
noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease." J Med 
Life 11(3): 243 -246. 
Janes, C.H. and Lindor, K.D. (1993). "Outcome of patients hospi[INVESTIGATOR_9244]."  Ann Intern Med 118: 96-98. 
Khan, F. Z., Perumpail, R. B., Wong, R. J. and Ahmed, A. (2015). "Advances in hepatocellular 
carcinoma: Nonalcoholic steatohepatitis -related hepatocellular carcinoma." World journal of 
hepatology 7(18): 2155 -2161. 
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., et al. (2017). "Once -weekly administration of a long -acting fibroblast growth factor 21 analogue modulates 
lipi[INVESTIGATOR_805], bone turnover markers, blood pressure a nd body weight differently in obese people with 
hypertriglyceridaemia and in non-human primates." Diabetes Obes Metab 19(12): 1762-1772. 
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., et al. 
(2005). "Design and va lidation of a histological scoring system for nonalcoholic fatty liver 
disease." Hepatology 41(6): 1313-1321. 
Lee, D. V., Li, D., Yan, Q., Zhu, Y., Goodwin, B., Calle, R., et al. (2014). "Fibroblast growth 
factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-
derived (hASC) adipocytes." PLoS One 9(11): e111767. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 123 
 Lee, P., Linderman, J., Smith, S., Brychta, R. J., Perron, R., Idelson, C., et al. (2013). "Fibroblast 
growth factor 21 (FGF21) and bone: is there a relationship in humans?" Osteoporos Int 24(12): 
3053-3057. 
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., 3rd, Feldman, H. I., et 
al. (2009). "A new equation to estimate glomerular filtration rate." Ann Intern Med 150(9): 604-
612. 
Li, M., Reynolds, C. M., Segovia, S. A., Gray, C. and Vickers, M. H. (2015). "Developmental 
Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on 
Susceptibility and Disease Severity in Later Life." BioMed research international 201 5: 437107-
437107. 
Lichtinghagen, R., Pi[INVESTIGATOR_9245], D., Bantel, H., Manns, M. P., Brand, K. and Bahr, M. J. (2013). "The 
Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut- off 
values." J Hepatol 59(2): 236-242. 
Loomba, R., Neuschwander -Tetri, B.A., Sanyal, A., Chalasani, N., Diehl, A.M., Terrault, N., et 
al. (2017). " Novel multicenter validation of association  between decline in MRI -PDFF and 
histologic response: a secondary analysis of FLINT trial." Poster presented at American  
Association for the St udy of Liver Diseases (AASLD).  
Loomba, R., Sanyal, A.J., Kowdley, K.V., Terrault, N., Chalasani, N.P., Abdelmalek, M.F., et al. 
(2019). "Factors associated with histologic response in adult patients with nonalcoholic steatohepatits. Gastroenterology  156: 88-95. 
Loomba, R., Sirlin, C.B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., et al. (2015). "Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by [CONTACT_9346] a randomized trial (MOZART trial)." 
Hepatology 61(4): 1239-1250. 
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. 
(1985). "Homeostasis model assessment: insulin resistance and beta -cell function from fasting 
plasma glucose and insulin concentrations in man." Diabetologia 28(7): 412-419. 
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., et al. (2016). 
"Hepatocellular Carcinoma in the Absence of Cirrhosis in [LOCATION_002] Veterans is Associated 
With Nonalcoholic Fatty Liver Disease." Clin Gastroenterol Hepatol 14(1): 124 -131.e121. 
Mu, J., Pi[INVESTIGATOR_9246], J., Li, Z., Skidmore, L., Li, N., Myler, H., et al. (2012). "FGF21 analogs of 
sustained action enabled by [CONTACT_9347]." Diabetes 61(2): 505-512. 
Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Orsnes-Leeming, D. J., Vainer, B., Gardner, S. D., 
et al. (2015). "Plasma Pro -C3 (N- terminal type III collagen propeptide) predicts fibrosis 
progression in patients with chronic hepatitis C." Liver Int 35(2): 429 -437. 
Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Goetz, R., et al. (2007). "BetaKlotho is required for metabolic activity of fibroblast growth factor 21." Proc Natl Acad 
Sci U S A 104(18): 7432-7437. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 124 
 Owen, B. M., Bookout, A. L., Ding, X., Lin, V. Y., Atkin, S. D., Gautron, L., et al. (2013). 
"FGF21 contributes to neuroendocrine control of female reproduction." Nat Med 19(9): 1153-
1156. 
Park, J. G., Xu, X., Cho, S., Hur, K. Y., Lee, M. S., Kersten, S., et al. (2016). "CREBH- FGF21 
axis improves hepatic steatosis by [CONTACT_9348]." Sci Rep 6: [ZIP_CODE]. 
Pi[INVESTIGATOR_9212], F., Sagnelli, E., Pasquale, G., and Gius ti, G. (1986). "Complications following 
percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies." J Hepatol 2: 
165-173. 
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., et al. 
(2011). "The Columbia -Suicide Severity Rating Scale: initial validity and internal consistency 
findings from three multisite studies with adolescents and adults." The American journal of 
psychiatry 168(12): 1266-1277. 
Rinella, M. E. (2015). "Nonalcoholic fatty liver disease: a systematic review." Jama 313(22): 
2263-2273. 
Rockey, D.C., Caldwell, S.H., Goodman, Z.D., Nelson, R.C., Smith, A.D., and American 
Association for the St udy of Liver Diseases.  (2009). "Liver biopsy." Hepatology 49: 1017-1044. 
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., 
Abdelmalek, M. F., et al. (2019). "Pegbelfermin (BMS-986036), a PEGylated fibroblast growth 
factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo -controlled, phase 2a trial." Lancet 392([ZIP_CODE]): 2705-2717. 
Saponaro, C., Gaggini, M., Carli, F. and Gastaldelli, A. (2015). "The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis." Nutrients 7(11): 9453 -
9474. 
Seeff , L.B., Everson, G.T., Morgan, T.R., Curto, T.M., Lee, W.M., Ghany, M.G., et al . (2010). 
"Complication rate of percutaneous liver biopsies among persons with advanced chronic liver 
disease in the HALT -C trial." Clin Gastroenterol Hepatol 8: 877 -883. 
Soderberg, C., Stal, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., et al. (2010). "Decreased survival of subjects with elevated liver function tests during a 28- year follow -up." 
Hepatology 51(2): 595 -602. 
Tapper, E. B. and Loomba, R. (2018). "Noninvas ive imaging biomarker assessment of liver 
fibrosis by [CONTACT_9349]." Nat Rev Gastroenterol Hepatol 15(5): 274-282. 
Torres, D. M., Williams, C. D. and Harrison, S. A. (2012). "Features, diagnosis, and treatment of 
nonalcoholic fatty liver disease."  Clin Gastroenterol Hepatol 10(8): 837-858. 
Vernon, G., Baranova, A. and Younossi, Z. M. J. A. P. T. (2011). "Systematic review: The 
epi[INVESTIGATOR_9247]- alcoholic fatty liver disease and non -alcoholic 
steatohepatitis in adults." Pharmacol Ther 34(3): 274-285. 
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., et al. (2012). 
"Fibroblast growth factor 21 promotes bone loss by [CONTACT_9350] -activated receptor gamma." Proc Natl Acad S ci U S A 109(8): 3143-3148. 
West,  J. and Card, T.R. (2010). "Reduced mortality rates following elective percutaneous liver 
biopsies." Gastroenterology 139: 1230-1237. 
Protocol BIO 89-100-002 
 
 
89bio Confidential Page 125 
 Woolsey, S. J., Beaton, M. D., Mansell, S. E., Leon-Ponte, M., Yu, J., Pin, C. L., et al. (2016). 
"A Fibroblast Growth Factor [ADDRESS_8674] Downregulates Hepatic CYP3A4 
in Nonalcoholic Fatty Liver Disease." Mol Pharmacol 90(4): 437-446. 
Woolsey, S. J., Mansell, S. E., Kim, R. B., Tirona, R. G. and Beaton, M. D. (2015). "CYP3A 
Activity and Expression in Nonalcoholic Fatty Liver Disease." Drug Metab Dispos 43(10): 1484-
1490. 
Younossi, Z., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., et al. (2019). 
"GS-06-Positive Results from REGENERATE: A Phase 3 Internationa l, Randomized, Placebo-
Controlled Study Evaluating Obeticholic Acid Treatment for NASH." Journal of Hepatology 70(1): e5. 
Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., et al. (2014). "Association between serum 
free fatty acid levels and nonalcohol ic fatty liver disease: a cross-sectional study." Sci Rep 4: 
5832. 
 